Spatial analysis of planar biological specimens

Abstract

In particular, methods are provided herein for analyzing planar biological samples.In some embodiments, the method may include: contacting oligonucleotide or conjugate comprising oligonucleotide with sample under conditions that oligonucleotide or conjugate specifically binds to the site in or on planar biological sample; carrying out one or more steps for releasing and / or extending oligonucleotide in situ to generate reporter probe; transferring reporter probe from sample to planar support that does not include array of oligonucleotide, so as to preserve the spatial relationship of reporter probe in sample; and (d) detecting reporter probe on support.

Description

[Technical field]

[0001] (CROSS REFERENCE TO RELATED APPLICATIONS) This application claims the benefit of U.S. Provisional Patent Application No. 63 / 214,701, filed June 24, 2021, and U.S. Provisional Patent Application No. 63 / 257,456, filed October 19, 2021, which are incorporated by reference in their entireties herein. [Background technology]

[0002] Protein expression, RNA expression and interactions between biomolecules in tissues can be investigated using various methods. For example, proximity assays can be performed on tissue sections and products can be detected in situ (Hegazy et al. (2020), Current Protocols in Cell Biology, 89(1):e115). In such methods, proximal target proteins or epitopes are bound by corresponding antibodies that bring together oligonucleotides conjugated to the antibodies. The oligonucleotides are ligated and amplified, for example, using rolling circle amplification (RCA). The amplification products can then be detected in tissue sections or sequenced after incorporation of spatial barcodes. Depending on the sequencing or detection, the proximal proteins are decoded. Other techniques for spatial analysis include subsequent immunohistochemistry using labeled antibodies or labeling RNA with various combinations and designs of fluorescent oligonucleotides.

[0003] However, these conventional methods are limited for several reasons: the detection of molecules present in tissue suffers from optical crowding, which limits the number of molecules that can be resolved in one image: when many molecules are crowded in the analysis area, the detection method loses resolution, which makes it difficult to produce high-resolution images.

[0004] Furthermore, amplification-based methods suffer from spatial crowding, i.e., they are limited by the number of molecules that can be physically located in one area. For example, RCA amplification generates large DNA amplification products that cluster in an area, making them difficult to distinguish from one another.

[0005] Furthermore, many of the conventional methods are time-consuming and labor-intensive because reactants diffuse in and out of tissue sections and it takes time to image the depth of tissue sections using so-called z-stacks. For example, multiplexed assays, such as single molecule fluorescence in situ hybridization (smFISH) assays, can take several days (see, for example, Shahet et al., Neuron 2016 92:342-357). Furthermore, biological samples often generate a significant amount of background signal, so images obtained from conventional methods are often not very clear, making detection of labeled molecules more difficult.

[0006] Therefore, a method for spatial analysis that overcomes these problems associated with conventional methods is desirable. Summary of the Invention

[0007] Provided herein is, inter alia, a method for analyzing planar biological samples.In some embodiments, the method may include contacting an oligonucleotide or a conjugate comprising an oligonucleotide with a sample under conditions in which the oligonucleotide or the conjugate specifically binds to a site in or on a planar biological sample, performing one or more steps in situ to release and / or extend the oligonucleotide to generate a reporter probe, transferring the reporter probe from the sample to a planar support that does not include an array of oligonucleotides so as to preserve the spatial relationship of the reporter probe in the sample, and detecting the reporter probe on the support.As described in more detail below, the method can be performed in a variety of different ways.

[0008] In some embodiments, the methods may comprise performing a proximity assay in situ on one or more pairs of binding agent-oligonucleotide conjugates bound to a sample to generate proximity assay reaction products, transferring the nucleic acid reaction products into or onto a support so as to preserve the spatial relationship of the proximity assay reaction products in the sample, and detecting the proximity assay reaction products in or on the support.

[0009] As described in more detail below, the proximity assay reaction products transferred to the support can be generated in a variety of different ways, for example, by ligation, primer extension, gap-fill / ligation or any hybridization between the oligonucleotides of the binder-oligonucleotide conjugate such that the sequence of one of the oligonucleotides is covalently linked to another oligonucleotide or copy thereof, and then transferring the first product to the support. Alternatively, the first product or unligated oligonucleotides can serve as a splint for ligating other oligonucleotides together to generate a second product. In these embodiments, the second product may be transferred to the support.

[0010] For example, in one non-limiting embodiment, the method can include performing a proximity assay in situ on one or more pairs of binder-oligonucleotide conjugates bound to a sample to generate a first product, and then transferring the first product or a second product (created via ligation supported by the first product) that includes a complementary sequence of the first product to a support. When the first products are transferred to the support, they can be cleaved from the binder prior to transfer.

[0011] The target bound by the binder-oligonucleotide conjugate can be proteinaceous, nucleic acid, or small molecule. Thus, in some embodiments, the binder-oligonucleotide conjugate can be composed of a binder (e.g., an antibody) conjugated to an oligonucleotide. In other embodiments, the binder-oligonucleotide conjugate can be composed of an oligonucleotide, where a portion of the oligonucleotide hybridizes to a specific sequence in a cellular RNA or gene, and another portion of the oligonucleotide does not hybridize to the RNA or gene. Depending on the binder-oligonucleotide conjugate used, the method can be used to test protein expression, post-translational modification, RNA expression, and genomic DNA, among others.

[0012] Depending on how it is implemented, the present method can avoid some of the problems associated with conventional methods.

[0013] For example, nucleic acid reaction products are transferred to a support and then analyzed, thus avoiding a major source of background, namely tissue sections.

[0014] In some cases, high-resolution images can be obtained by imaging the sample in one plane. Thus, unlike some conventional methods, some of the embodiments disclosed herein avoid acquiring a z-stack of images during detection because the molecule can be moved to a planar 2D surface. Producing a z-stack can be time-consuming and reduce the throughput of the analysis. Thus, the methods disclosed herein, depending on how they are implemented, can avoid the need to image a z-stack, potentially saving time and cost.

[0015] Furthermore, in some cases, the method may include repeated cycles of labeling and detection. Since the transferred DNA molecules can be attached to the support using very stable chemical reactions, including covalent attachment, or for example, using biotin-avidin, which is generally stable even after multiple cycles of labeling and washing, the method may allow for continuous and combined detection of molecules over a very large number of cycles. In particular, the DNA molecules attached to the support withstand multiple labeling and washing. This may be a significant challenge when imaging molecules in tissue material, since the tissue slowly disintegrates over detection and washing cycles. Since only a small number of barcodes or barcode combinations are detected in a cycle, the molecules labeled in a particular cycle are more spaced apart compared to when all analyzed molecules are detected in the same cycle, thereby avoiding optical crowding, i.e., multiple signal emission from one location. Thus, the possibility of using more detection cycles also allows for the detection of more (and different) target molecules (more advanced multiplex detection) when the molecules are firmly immobilized. The methods disclosed herein are easier to multiplex as multiple cycles of labeling and detection can be directed to different target barcodes or combinations of barcodes that may be contained on oligonucleotides conjugated to different binding agent-oligonucleotide conjugates.

[0016] In some cases, bridging oligonucleotides are used to amplify the signal from the barcode or combination of barcodes, thereby providing a higher signal-to-noise ratio. For example, the reading of molecules on a support performed in the methods disclosed herein may be advantageous due to high spatial resolution compared to the reading of molecules performed indirectly in certain conventional methods, for example, by sequencing performed in certain amplification-based methods. By transferring the nucleic acid reaction product to the support, it becomes easier to perform single molecule detection with lower background compared to analysis in tissues where background fluorescence can be high.

[0017] In conventional amplification-based methods, multiple copies of the target nucleic acid are generated, for example, via RCA. The presence of multiple copies of the same nucleic acid target can result in physical crowding of the nucleic acid in the sample being tested. Furthermore, amplification-based methods usually generate a variable number of copies of the target, which results in a variable signal from each molecule. However, the methods disclosed herein have embodiments in which a defined number of molecules can be used to label each molecular target for detection, and each single molecule is detected using a predefined number of labels, resulting in a more uniform detection signal. Furthermore, compared to RCA-based approaches in which a large bundle of DNA is created for each detected molecule, the methods have embodiments in which the labels and labeled oligonucleotides used for detection can be completely washed away between each detection cycle, reducing physical crowding between molecules and leaving only the reporter molecules attached to the surface. Thus, depending on how the methods are implemented, the methods disclosed herein can avoid the problem of physical crowding of the target nucleic acid in the sample.

[0018] Furthermore, in some embodiments of the method, reporter probe is generated using the initial nucleic acid reaction product as template.The advantage of using reporter probe is that shorter oligonucleotides can be conjugated to binding agent, which in turn increases the resolution of the method and improves the kinetics and binding of binding agent to target.Conjugating long oligonucleotides, for example, to antibodies, can affect their ability to bind effectively to epitopes in tissues more than shorter oligonucleotides.

[0019] Furthermore, supports containing nucleic acids are very stable and can be easily stored for long periods of time without loss of the relevant information.

[0020] As mentioned above, the reporter molecule transferred to the support is a nucleic acid. Because the reporter molecule is a nucleic acid, different labeled probes can be hybridized to the same molecule by hybridizing one probe to the reporter molecule, imaging the support, dehybridizing the probe (or deactivating the label), and then hybridizing a different probe to a different site in the reporter molecule. These hybridization / reading / deactivation / hybridization steps can be repeated as many times as necessary. Since the labeling system allows single molecule resolution, the image can appear as punctate spots, with each spot corresponding to a probe hybridization event. This allows multiple repeated rounds of probe hybridization to be performed to determine which probe hybridizes to a particular site in the sample. This allows the support to be analysed in a multiplex manner (e.g. using the "coding" system described in Goransson (Nucl. Acids Res 2009 37 e7)) thereby making it possible to map binding sites corresponding to at least 10, at least 50, at least 100, at least 200, at least 500, at least 1000, at least 10000 genes or proteins.

[0021] In some embodiments, the planar sample may be generated by passing a suspension of cells through a filter, and the cells are retained on the filter. This embodiment may be utilized to analyze the suspension of cells. In some embodiments, the method may include (a) filtering the suspension of cells through a porous capillary membrane, thereby distributing the cells on the membrane; (b) placing the membrane on the support with the cell side of the membrane facing the planar support; (c) transferring nucleic acid from the cells into or onto the support, so as to preserve the spatial relationship of the nucleic acid in the cells; (d) removing the porous capillary membrane and the cells from the support; and (e) spatially analyzing the nucleic acid transferred to the support. Further details of the method are described below. [Brief description of the drawings]

[0022] Those skilled in the art will appreciate that the following drawings are for illustrative purposes only and are not intended to limit the scope of the present teachings in any way. [Figure 1] Some of the principles of the method are illustrated briefly below. [Figure 2A] Several ways in which the method can be implemented are presented. [Figure 2B] Several ways in which the method can be implemented are presented. [Figure 2C] Several ways in which the method can be implemented are presented. [Figure 2D] Several ways in which the method can be implemented are presented. [Figure 2E] Several ways in which the method can be implemented are presented. [Figure 2F] Several ways in which the method can be implemented are presented. [Figure 2G] Several ways in which the method can be implemented are presented. [Figure 2H] Several ways in which the method can be implemented are presented. [Figure 2I] Several ways in which the method can be implemented are presented. [Figure 2J]Several ways in which the method can be implemented are presented. [Figure 2K] Several ways in which the method can be implemented are presented. [Figure 2L] Several ways in which the method can be implemented are presented. [Figure 2M] Several ways in which the method can be implemented are presented. [Diagram 3] 1 illustrates diagrammatically how some embodiments of the method may be implemented; [Figure 4] 1 illustrates how some embodiments of the method can be implemented. [Diagram 5] We show how a barcode can be detected on a support using a bridging probe, a detection probe and a labeling probe. [Figure 6A] 1 illustrates an exemplary method by which a proximity assay can be performed. [Figure 6B] 1 illustrates an exemplary method by which a proximity assay can be performed. [Figure 6C] 1 illustrates an exemplary method by which a proximity assay can be performed. [Figure 7] Transfer of fluorescent biotinylated DNA oligos from tissue (A) to an avidin-coated glass coverslip (B). A) Fluorescent image of the tissue after transfer, where some of the oligos are still present. B) The transferred coverslip, corresponding to (A), where some of the oligos have been transferred. [Figure 8] Diagram of TMA illustrating the location of different cell lines and tissue types. [Figure 9] Panel A: Reporter molecules created by proximity ligation assay were detected by HCR after transfer to a functionalized coverslip. Panel B: The remaining reporter molecules were chromogenically stained in tissue TMAs, where only the DAB staining after color deconvolution is shown. Scale bar is 1 mm in both images. [Figure 10] The resulting sequencing image data are shown as bright spots on a dark background. [Figure 11]The transferred reporter molecules are shown. Each reporter molecule is represented by a single dot. The eight circles at the bottom of the image correspond to the TMAs. [Figure 12] Detection of the circular reporter molecule is shown. The detection system is used in cycles 2, 4, 6 and 8, while cycles 3, 5, 7 and 9 represent stripping or washing cycles. Cycle 1 shows the sample area prior to injection of any detection system. [Figure 13A] The detected reporter molecules are shown. [Figure 13B] The detected reporter molecules are shown. [Figure 13C] The detected reporter molecules are shown. [Figure 13D] Detected reporter molecules are shown. Each figure represents a 4-FoV region that is a subset of the larger sampled region shown in FIG. 11. 13A) Spot locations identified using detection system 1 (L-Probe-7-DetA). 13B) Spot locations identified using detection system 2 (L-Probe-8-DetB). 13C) Spots / reporter molecules co-detected using detection systems 1 and 2. 13D) Spot locations identified using fluorophores directly conjugated to the reported molecules. [Figure 14] 1 illustrates generally some of the principles of how filters can be used to collect cells. [Figure 15] 15 illustrates a schematic diagram of an embodiment of the method shown in FIG. 14.

[0023] definition Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.

[0024] All patents and publications, including all sequences disclosed within such patents and publications, referred to herein are expressly incorporated by reference.

[0025] Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation. Amino acid sequences are written left to right in amino to carboxy orientation, respectively.

[0026] The headings provided herein are not intended to be limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0027] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs. Singleton et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994), and Hale & Markham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide those skilled in the art with the general meaning of many of the terms used herein. Furthermore, for clarity and ease of reference, certain terms are defined below.

[0028] As used herein, the term "multiplexing" refers to simultaneously detecting and / or measuring multiple biological features of interest, e.g., protein epitopes, in a sample.

[0029] As used herein, the terms "antibody" and "immunoglobulin" are used interchangeably herein and are well understood by those skilled in the art. These terms refer to a protein consisting of one or more polypeptides that specifically bind to an antigen. One form of antibody constitutes the basic structural unit of an antibody. This form is a tetramer, consisting of two pairs of identical antibody chains, each pair having one light chain and one heavy chain. In each pair, the variable regions of the light and heavy chains together are involved in binding to the antigen, and the constant regions are involved in the effector functions of the antibody.

[0030] The terms "antibody" and "immunoglobulin" include antibodies or immunoglobulins of any isotype that retain specific binding to an antigen, including, but not limited to, Fab, Fv, scFv, and Fd fragments, chimeric antibodies, humanized antibodies, minibodies, single chain antibodies, and fusion proteins comprising an antigen-binding portion of an antibody and a non-antibody protein. Fab', Fv, F(ab')2, and / or other antibody fragments that retain specific binding to an antigen, as well as monoclonal antibodies, are also encompassed by the terms. Antibodies can exist in a variety of other forms, including, for example, Fv, Fab and (Fab')2, as well as bifunctional (i.e., bispecific) hybrid antibodies (e.g., Lanzavecchia et al., Eur. J. Immunol. 17, 105 (1987)), and single chains (e.g., Huston et al., Proc. Natl. Acad. Sci. USA, 85, 5879-5883 (1988) and Bird et al., Science, 242, 423-426 (1988)), which are incorporated herein by reference. (See generally, Hood et al., "Immunology", Benjamin, NY, 2nd ed. (1984) and Hunkapiller and Hood, Nature, 323, 15-16 (1986)).

[0031] The term "specific binding" refers to the ability of a binding member to bind preferentially to another binding member that is present in a homogenous mixture of different molecules.

[0032] In certain embodiments, the affinity between the binding members when specifically bound in the complex is greater than or equal to 10 -6 Less than M, 10 -7 Less than M, 10 -8 Less than M, 10 -9 Less than M, 10 -9 Less than M, 10 -11 Less than M or about 10 -12 K less than M or less than D (dissociation constant).

[0033] A "plurality" includes at least two members. In certain cases, a plurality may be at least 2, at least 5, at least 10, at least 100, at least 1000, at least 10,000, at least 100,000, at least 10 6 Pieces, at least 10 7 Pieces, at least 10 8 10 or at least 10 9 In certain cases, a plurality may have from 2 to 100 or from 5 to 100 members.

[0034] As used herein, the term "labeling" refers to the step of binding a binding agent to a specific site in a sample (e.g., a site containing an epitope for the binding agent (e.g., an antibody) used) such that the presence and / or abundance of the site can be determined by assessing the presence and / or abundance of the binding agent. The term "labeling" refers to a method for producing a labeled sample in which any necessary steps are performed in any convenient order, so long as the required labeled sample is produced. For example, in some embodiments, as exemplified below, the sample can be labeled using a labeled probe that can be detected to determine the distribution of nucleic acids on the support.

[0035] As used herein, the term "planar biological sample" refers to a substantially flat, i.e., two-dimensional, material (e.g., glass, metal, ceramic, organic polymer surface or gel) that contains cells or any combination of biomolecules derived from cells, such as proteins, nucleic acids, lipids, oligosaccharides / polysaccharides, biomolecule complexes, organelles, cell debris or secretions (exosomes, microvesicles). Planar biological samples can be made, for example, by growing cells on a planar support, by depositing the cells on the planar support, e.g., by centrifugation, by cutting a three-dimensional object containing cells into slices and placing the slices on a planar support, i.e., by generating tissue slices, adsorbing cellular components onto a surface that is functionalized with affinity agents (e.g., antibodies, haptens, nucleic acid probes), introducing biomolecules into a polymer gel or transferring them electrophoretically or by other means onto the polymer surface. Cells or biomolecules can be fixed using any number of reagents, such as formalin, methanol, paraformaldehyde, methanol:acetic acid, glutaraldehyde; bifunctional crosslinkers, such as bis(succinimidyl) suberate, bis(succinimidyl) polyethylene glycol, etc. This definition is intended to encompass cellular samples (e.g., tissue sections, etc.), electrophoretic gels and their blots, Western blots, dot blots, ELISA, antibody microarrays, nucleic acid microarrays, etc. Depending on the particular technique used to prepare the sections, planar biological samples can have thicknesses anywhere from 20-50 nm and up to 5-10 μm.

[0036] As used herein, the term "tissue section" refers to a piece of tissue obtained from a subject, optionally fixed, sectioned, and mounted on a planar support, such as a microscope slide.

[0037] As used herein, the term "formalin-fixed paraffin embedded (FFPE) tissue section" refers to a section of tissue, e.g., a biopsy sample, obtained from a subject, fixed in formaldehyde (e.g., 3% to 5% formaldehyde in phosphate-buffered saline) or Bouin's solution, embedded in wax, cut into thin sections, and then mounted on a microscope slide.

[0038] As used herein, the phrase "in situ" refers to a particular location or location in a planar biological sample. For example, a "binding agent bound in situ to a sample" indicates that the binding agent is bound to a particular location in a planar biological sample.

[0039] A "diagnostic marker" is a specific biochemical in the body that has particular molecular characteristics that make it useful for detecting disease, measuring the progression of disease or the effectiveness of treatment, or measuring a process of interest.

[0040] A cell "indicative of a disease state" is a cell whose presence in a tissue indicates that the animal in which the tissue is located (or from which the tissue is obtained) is afflicted with a disease or disorder. By way of example, the presence of one or more mammary gland cells in the lung tissue of an animal is an indication that the animal is afflicted with metastatic breast cancer.

[0041] The term "complementary site" is used to refer to a nucleic acid having a sequence that is complementary to an epitope of an antibody or aptamer, or an oligonucleotide probe. Specifically, when the binding agent is an antibody or aptamer, the complementary site for the binding agent is the epitope in the sample to which the antibody or aptamer binds. The epitope may be a conformational epitope, or may be a linear epitope, for example, composed of an amino acid sequence. When the binding agent is an oligonucleotide probe, the complementary site of the binding agent is a complementary nucleic acid (e.g., an RNA or a region in a genome).

[0042] As used herein, the term "epitope" is defined as the structure, e.g., a stretch of amino acids, on an antigen molecule that is bound by an antibody or aptamer. An antigen can have one or more epitopes. In many cases, an epitope is about 5 amino acids or sugars in size. Those skilled in the art will generally understand that the overall three-dimensional structure or specific linear sequence of a molecule can be the primary criterion for antigen specificity.

[0043] A "subject" of diagnosis or treatment can be a plant or an animal, including a human. Non-human animal subjects of diagnosis or treatment include, for example, livestock and pets.

[0044] As used herein, the term "incubating" refers to maintaining the sample and binding agent under conditions suitable for specific binding of the binding agent to a molecule (e.g., an epitope or complementary nucleic acid) in the sample, which conditions include time period, one or more temperatures, appropriate binding buffers, and washing.

[0045] As used herein, the term "binding agent" refers to an agent that can specifically bind to a complementary site in a sample. Exemplary binding agents include oligonucleotide probes, antibodies, and aptamers. When antibodies or aptamers are used, they often may bind to protein epitopes.

[0046] The terms "nucleic acid" and "polynucleotide" are used interchangeably herein to describe polymers of any length, and refer to nucleotides, e.g., deoxyribonucleotides, ribonucleotides, or combinations thereof, composed of more than about 2 bases, more than about 10 bases, more than about 100 bases, more than about 500 bases, more than 1000 bases, up to about 10,000 bases, or more bases, which can be produced enzymatically or synthetically (e.g., PNAs, as described in U.S. Pat. No. 5,948,902 and references cited therein), and which can hybridize to naturally occurring nucleic acids in a sequence-specific manner similar to that of two naturally occurring nucleic acids, e.g., participate in Watson-Crick base pairing interactions. Naturally occurring nucleotides include guanine, cytosine, adenine, thymine, and uracil (G, C, A, T, and U, respectively). DNA and RNA have deoxyribose and ribose sugar backbones, respectively, and the backbone of PNA consists of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. In PNA, various purine and pyrimidine bases are attached to the backbone by methylene carbonyl bonds. Locked nucleic acid (LNA), often referred to as inaccessible RNA, is an RNA molecule that contains modified RNA nucleotides. The ribose moiety of the LNA nucleotide is modified with an additional bridge connecting the 2' oxygen and the 4' carbon. The bridge "locks" the ribose in a 3'-endo (North) conformation, often found in A-form duplexes. LNA nucleotides can be mixed with DNA or RNA residues in an oligonucleotide whenever desired. The term "unstructured nucleic acid" or "UNA" refers to a nucleic acid that contains non-natural nucleotides that bind to each other with reduced stability. For example, unstructured nucleic acids can contain G' and C' residues, which correspond to non-naturally occurring forms, i.e., analogs, of G and C that base pair with each other with reduced stability but retain the ability to base pair with naturally occurring C and G residues, respectively.Unstructured nucleic acids are described in US2005 / 0233340, which is incorporated herein by reference for its disclosure of UNAs.

[0047] As used herein, the term "oligonucleotide" refers to a multimer of at least 10 nucleotides, e.g., at least 15 nucleotides or at least 30 nucleotides. In some embodiments, oligonucleotides may range in length from 15 to 200 nucleotides or more. Any oligonucleotide used herein may be composed of G, A, T, and C, or bases that can reliably base pair with complementary nucleotides. Examples of such bases include 7-deaza-adenine, 7-deaza-guanine, adenine, guanine, cytosine, thymine, uracil, 2-deaza-2-thio-guanosine, 2-thio-7-deaza-guanosine, 2-thio-adenine, 2-thio-7-deaza-adenine, isoguanine, 7-deaza-guanine, 5,6-dihydrouridine, 5,6-dihydrothymine, xanthine, 7-deaza-xanthine, hypoxanthine, 7-deaza-xanthine, 2,6 diamino-7-deazapurine, 5-methyl-cytosine, 5-propynyl-uridine, 5-propynyl-cytidine, 2-thio-thymine, or 2-thio-uridine, although many others are known.As mentioned above, the oligonucleotide may be, for example, an LNA, PNA, UNA, or morpholino oligomer. As used herein, an oligonucleotide may contain natural or non-natural nucleotides or linkages.

[0048] As used herein, in the context of reading a fluorescent signal, the term "reading" refers to obtaining an image by scanning or microscopy, where the image shows the pattern of fluorescence and the intensity of the fluorescence within a field of view.

[0049] As used herein, for example, in the context of reading a fluorescent signal generated by the addition of a fluorescent nucleotide, the term "signal generated by" refers to a signal emitted directly from the fluorescent nucleotide or indirectly via energy transfer to another fluorescent nucleotide (i.e., by fluorescence resonance energy transfer (FRET)).

[0050] As used herein, the term "cleavable linker" refers to a linker that contains a bond that can be selectively cleaved by a particular stimulus, for example a reducing agent such as TCEP or DTT.

[0051] As used herein, the phrase "specific binding pair" includes a "first binding member" and a "second binding member" that have binding specificity for each other. The binding members of a binding pair may be naturally occurring or wholly or partially synthetically produced. A binding member has an area or cavity on its surface that specifically binds to, and is therefore complementary to, a particular spatial and polar configuration of the other binding member of the binding pair. Examples of specific binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor-ligand, nucleic acids that hybridize to each other, and enzyme-substrate.

[0052] As used herein, the term "binder-oligonucleotide conjugate" or "binder conjugate" refers to a binder, e.g., an antibody, aptamer, or oligonucleotide probe, that is non-covalently (e.g., via streptavidin / biotin interactions) or covalently (e.g., via a "click" reaction (see, e.g., Evans Aus. J. Chem. 2007 60:384-395)) attached to a single-stranded oligonucleotide such that the binder can still bind to its binding site. The nucleic acid and binder can be attached via several different methods, including using cysteine-reactive maleimides or halogen-containing groups. The binder and oligonucleotide may be attached proximal or at the 5' end of the oligonucleotide, proximal or at the 3' end of the oligonucleotide, or anywhere in between. The bond between the binder and the oligonucleotide in a binder-oligonucleotide conjugate can be cleavable such that the nucleic acid reaction product can be released from the corresponding binder via cleavage of a cleavable linker. As exemplified below, a binder-oligonucleotide conjugate may be comprised of a single oligonucleotide, where one region of the polynucleotide (the "probe" portion of the oligonucleotide, which may be a region of 15-50 bases in length) hybridizes to a target nucleic acid (e.g., RNA) in a sample, and other regions do not hybridize to the target and are free to participate in other reactions described herein.

[0053] The oligonucleotide that binds to the binding agent in a binding agent-oligonucleotide conjugate may be referred to herein as the "first oligonucleotide."

[0054] As used herein, the phrase "proximity assay" refers to an assay in which new DNA products (e.g., ligation products or primer extension products) are generated only when two binding events are in proximity. In a proximity assay, an oligonucleotide binds to a target-specific binding agent, such as an antibody, an aptamer, or an oligonucleotide probe. If the target molecule is DNA or RNA, the oligonucleotide can have a sequence complementary to the target nucleic acid. If the binding agent binds to a site in the sample that is in close proximity, the oligonucleotides conjugated to these binding agents (the "first" oligonucleotides) will be in close proximity, thereby allowing the generation of new DNA products. New DNA products can be generated by a variety of different methods. For example, new DNA products can be generated by an initial enzymatic reaction between one first oligonucleotide and another oligonucleotide (e.g., by ligating one end of the oligonucleotide to a nearby oligonucleotide, by extending one end of the oligonucleotide using the nearby oligonucleotide as a template, or by joining one end of the oligonucleotide to a nearby oligonucleotide via a templated gap-fill / ligation reaction, etc.). An example involving ligating two first oligonucleotides together is shown in FIG. 6A. In other embodiments, the new DNA product may be templated by adjacent first oligonucleotides, but does not involve ligation between two first oligonucleotides. See, for example, FIG. 6B. FIG. 6C shows another product (called a "reporter probe") that is templated by the first product (FIG. 6B) generated by joining two first oligonucleotides or two adjacent oligonucleotides together. In FIGS. 6A-6C, the ligation junction is indicated by an x. Detection of the nucleic acid reaction product indicates that the corresponding binder-oligonucleotide conjugate is bound to the adjacent site. Thus, the binder-oligonucleotide conjugate is bound to the sample, and then a reaction (e.g., ligation, gap fill / ligation and / or primer extension reaction) is performed while the conjugate is bound to the sample.A product is generated only if two binder-oligonucleotide conjugates bind to adjacent sites. Specific non-limiting examples of proximity assays include proximity extension assay (PEA) and proximity ligation assay (PLA). For clarity, a proximity assay may involve an initial enzymatic reaction (e.g., ligation, etc.) occurring between a first oligonucleotide (i.e., an oligonucleotide attached to a binder) and, optionally, a second enzymatic reaction occurring between other oligonucleotides (e.g., reporter oligonucleotides) that enzymatically react with each other (e.g., ligate with each other) using the product of the initial reaction as a template. Alternatively, a proximity assay may involve an initial enzymatic reaction between the first oligonucleotides that are in proximity to each other and other oligonucleotides (e.g., reporter oligonucleotides) that enzymatically react with each other (e.g., ligate with each other) in a reaction that is templated by one or more other oligonucleotides that may act as splints or provide overhangs. Examples are shown in Figures 6A-6C, but other examples will be apparent.

[0055] As used herein, the phrase "proximity assay reaction product" refers to a nucleic acid product of a proximity assay. As explained below, such a product comprises sequences from two oligonucleotides or their complementary sequences, which are bound together only in the presence of a proximity binding event. The exact nature of the proximity assay reaction product may vary depending on how the assay is performed. In some embodiments, the proximity assay reaction product may be the product of an initial reaction that joins two first oligonucleotides together (by ligation or a gap-fill / ligation reaction). In these embodiments, the proximity assay reaction product comprises the same sequence as the two oligonucleotides that were bound together. In other embodiments, the proximity assay reaction product may be the product of an initial reaction that extends the 3' ends of the oligonucleotides to each other. In these embodiments, the proximity assay reaction product comprises the same sequence as one of the oligonucleotides and the complementary sequence of the other. In some embodiments, the proximity assay reaction product may be a copy of the initial product. In these embodiments, a reporter oligonucleotide may be hybridized to the initial product and then ligated together, as shown diagrammatically in FIG. 6B and FIG. 4. In other embodiments, the proximity assay reaction product may comprise a sequence of two or three oligonucleotides that are bound to each other in a reaction templated by two adjacent first oligonucleotides, as shown in Figure 6C.

[0056] The phrase "proximity extension assay" is intended to refer to a proximity assay that relies on primer extension, in which one oligonucleotide uses the other as a template. In this assay, oligonucleotides conjugated to two binder-oligonucleotide conjugates that are bound to adjacent sites hybridize to each other via complementary sequences at their 3' ends. The proximity extension assay then involves extending the 3' ends of the hybridized oligonucleotides, for example, using a polymerase and using the hybridized oligonucleotides as templates, to generate nucleic acid reaction products. The resulting nucleic acid reaction products (or their complementary sequences) indicate that the corresponding binder-oligonucleotide conjugates are bound to adjacent sites. Specific details of PEA are described in Di Giusto et al. (2005), Nucleic Acids Research, 33(6,e64):1-7, Lundberg et al. (2011) and Nucleic Acids Research, Vol. 39, No. 15, and Greenwood et al. (2015), Biomolecular Detection and Quantification, Vol. 4:10-16.

[0057] The phrase "proximity ligation assay" or PLA is intended to refer to a proximity assay in which one oligonucleotide is ligated to another oligonucleotide. Such ligation may include blunt-end ligation of single-stranded or double-stranded oligonucleotides, splint-mediated ligation of single-stranded oligonucleotides, or ligation of double-stranded oligonucleotides with complementary overhangs, e.g., overhangs that include restriction enzyme recognition sites. In certain splint-mediated ligations, the oligonucleotide hybridizes to the splint to leave a gap between the two ends of the oligonucleotide. In such cases, the proximity ligation assay involves sealing the gap using a polymerase in a "gap-fill" reaction, and then ligating the 3' end of the extended oligonucleotide to the 5' end of another oligonucleotide. Regardless of the method used to ligate the oligonucleotides, the nucleic acid reaction products resulting from the ligation are analyzed. The resulting nucleic acid reaction products indicate that the corresponding binder-oligonucleotide conjugates are bound to adjacent sites. Specific details of PLA are described in Fredriksson et al. (2002), Nature Biotechnology, 20: 473-477; Gullberg et al. (2004), PNAS, 101(22): 8420-8424; Wang et al. (2021), Applied Microbiology and Biotechnology, Vol. 105, pages 923-935; and Greenwood et al. (2015), Biomolecular Detection and Quantification, Vol. 4: 10-16.

[0058] As used herein, the phrase "preserves spatial relationship" characterizes how nucleic acid reaction products are transferred from a planar biological sample to a support. In particular, when nucleic acid reaction products are transferred from a planar biological sample to a support in a manner that preserves spatial relationship, the relative positions in the xy plane of different nucleic acid reaction products present in the planar biological sample do not change substantially when the nucleic acid reaction products are transferred onto the support. For example, the relative positions of different nucleic acid reaction products on the support may shift slightly from the corresponding relative positions in the planar biological sample due to lateral diffusion of the nucleic acid reaction products during transfer. Thus, the position of the nucleic acid reaction product on the support indicates the position of the nucleic acid reaction product on the planar biological sample. Molecules (e.g., reaction products or reporter probes) are transferred from a planar sample to a planar support in a manner that preserves the spatial relationship of the molecules in the sample, most commonly by placing the support on the sample (or vice versa) and directionally transferring the molecules onto the support, so that the molecules move (approximately) parallel to each other from the sample onto the support where they attach. When imaging the planar support, the transferred molecules are positioned as a mirror image compared to the original sample. In an exemplary embodiment, this can be done by placing a planar support (e.g., a coverslip or other slide) over the sample mounted on the slide such that the sample is sandwiched between the substrate and the slide. Molecules can move, for example, via diffusion, but the movement can be assisted by electrostatic, electric, magnetic, or other forces. In some embodiments, there can be a small gap (e.g., less than 1 mm, less than 0.5 mm, less than 0.2 mm, less than 100 μm, less than 50 μm, less than 10 μm, less than 5 μm, or less than 1 μm), which can optionally be filled with a transfer buffer (e.g., a low salt buffer). The gap can also be maintained using physical structures, spacers, or beads positioned between the surfaces.

[0059] In another exemplary embodiment, molecules transferred from a planar sample are transferred to a support on which the planar sample is located.

[0060] The term "proximal" or the phrase "proximally located target site" as used herein with respect to the location of the target site means that the target site is close enough so that the oligonucleotides attached to the binder-oligonucleotide conjugate that bind to the target site interact with each other, for example, by hybridization or ligation. The target sites can be on the same molecule, for example, two epitopes of one protein. The target sites can also be on different molecules, for example, two epitopes of two different proteins. The target sites can be on any combination of different types of molecules, for example, proteins, RNA, DNA, lipids, carbohydrates, etc. The distance between the sites that can be referred to as "proximally located target sites" depends on the length of the oligonucleotide attached to the binder-oligonucleotide conjugate and the presence of any linker between the binder and the oligonucleotide. Typically, proximally located target sites are located at a distance of less than 50 nm, for example, less than 30 nm, less than 20 nm, less than 10 nm, or less than 5 nm.

[0061] As used herein, the phrase "planar support" refers to a support to which nucleic acid reaction products from an analyzed planar biological sample are transferred. A wide variety of different substrates can be used as planar supports. Planar supports can be made of any suitable support material, such as glass, modified and / or functionalized glass, hydrogels, films, membranes, plastics (including, for example, acrylics, polystyrene, copolymers of styrene with other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon®, cyclic olefins, polyimides, etc.), nylon, ceramics, resins, Zeonor, silica or silica-based materials (including silicon, silicon wafers, and modified silicon), carbon, metals, inorganic glass, optical fiber bundles, and polymers (e.g., polystyrene, cyclic olefin copolymer (COC), cyclic olefin polymer (COP), polypropylene, polyethylene, and polycarbonate).

[0062] As used herein, the term "extending" refers to a ligation reaction (where another oligonucleotide is ligated to the end of an oligonucleotide), a primer extension reaction (where an oligonucleotide is extended using a polymerase), a gap fill / ligation reaction, or any combination thereof.

[0063] As used herein, the term "release" refers to the event of placing a molecule in solution untethered to a support. Release can be accomplished by cleavage of covalent bonds (which can be chemically, photo-, or enzymatically induced), by cleavage of non-covalent bonds, and by dehybridization of the molecule from another molecule (e.g., by heat or by using a denaturing agent).

[0064] As used herein, the phrase "three-dimensional support" is intended to refer to a three-dimensional permeable solid through which DNA molecules can move. In many cases, the three-dimensional support can be a cross-linked matrix, such as a gel.

[0065] As used herein, a "porous capillary membrane" refers to a membrane that has relatively densely packed individual capillaries that span the thickness of the membrane, i.e., from one side of the membrane to the other, thereby allowing liquids to pass from one side of the membrane to the other, but not particles. Examples of porous capillary membranes include, but are not limited to, anodized aluminum oxide membranes (see below), nanochannel glass membranes, track-etched membranes, and polytetrafluoroethylene. Nanochannel glass membranes are made of glass and have a high density of uniform channels with diameters ranging from 15 micrometers to 15 nanometers (see, e.g., Tonucci et al., Advances in Nanophotonics II, AIP Conference Proceedings, 2007 959:59-71; Pearson et al., Science 1995 270:68-70 and Tonucci et al., Science 1992 258:783-785, as well as U.S. Patent Nos. 5,306,661; 5,332,681; 5,976,444; 6,087,274; 6,376,096; 6,483,640 and 6,599,616, which are incorporated by reference). Track-etched membranes are made from transparent polymers (such as polycarbonate, polyethylene terephthalate, or polyimide) containing pores with diameters ranging from 0.01 μm to 30 μm created by a combination of charged particle bombardment (or irradiation) and chemical etching. Other porous membranes of interest include, but are not limited to, amorphous fluoropolymers such as NAFION™, TEFLON AF™, FEFLON FEIP™, and CYTOP™ (DuPont Fluoroproducts, Fayetteville, NC). As will be appreciated, porous capillary membranes may have a surface (e.g., a coated surface or a chemically modified surface) that is different from the material from which the membrane is made. For example, the surface of a porous capillary membrane may have altered charge characteristics, or altered hydrophobic or hydrophilic properties.In some embodiments, the surface can be coated with aminosilane, poly-lysine, or another compound to provide a positive charge that helps retain cells on the surface. Alternatively or additionally, the surface can have a thin layer of metal (e.g., titanium, gold) deposited therein, or can be bound to other agents that modify the surface properties of the filter.

[0066] As used herein, the term "anodized aluminum film" includes the standard self-assembled nanoporous film structure that is produced when Al is anodized in certain acidic media. By the deposition voltage, type of acid, and other parameters, the internal diameter of the pores in the film, the distance between the centers of adjacent pores in the film, and the distance between the edges of adjacent pores in the film can be controlled. Anodized aluminum films are substantially transparent when wet. Anodized aluminum oxide films, their properties, and methods for making such films have been reviewed in detail in various publications, including, but not limited to, Li et al. (Chem. Mater 1998 10:2470-2480), Santos et al. (Trends on Analytical Chemistry 2013 44:25-38), Ingham et al. (Biotechnology Advances 30 2012 1089-1099), and Poinern et al. (Materials 2011 4:487-526, the teachings of which are incorporated herein by reference). Anodized aluminum oxide films are commercially available under the trade name ANOPORE™, for example from SPI Supplies (West Chester, PA), and from other vendors, such as Sykera Technologies Inc. (Longmont, CO) and Sigma-Aldrich (St. Louis, MO), and can be purchased together with a support ring.

[0067] Other definitions of terms may appear throughout the specification. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0068] general principle Provided herein, among other things, is a method for analyzing planar biological samples. In some embodiments, the method may include contacting an oligonucleotide or a conjugate (i.e., an oligonucleotide, such as an antibody-oligonucleotide conjugate) comprising an oligonucleotide with a planar biological sample under conditions in which the oligonucleotide or conjugate specifically binds to a site in or on the sample, performing one or more steps to release and / or extend the oligonucleotide in situ and generate a reporter probe, transferring the reporter probe from the sample to a planar support that does not include an array of oligonucleotides so as to preserve the spatial relationship of the reporter probe in the sample, and detecting the reporter probe on the support. As described in more detail below, the method can be carried out in a variety of different ways. Some of the general principles of the method are shown in FIG. 1.

[0069] As shown in Figures 2A-2M, the method can be carried out in several different ways. For example, in some embodiments, the method can include hybridizing an oligonucleotide to the sample under conditions in which the oligonucleotide hybridizes to endogenous RNA or DNA in the sample, and joining together any oligonucleotides that hybridize to adjacent sites in the RNA or DNA via ligation or gap-fill / ligation. In other embodiments, the sample includes ligation products from a proximity ligation assay. In other embodiments, the method can include hybridizing an oligonucleotide to the sample under conditions in which the oligonucleotide hybridizes to the ligation product, and joining together any oligonucleotides that hybridize to adjacent sites in the ligation product via ligation or gap-fill / ligation reactions. In some of these embodiments, the oligonucleotides may be exonuclease sensitive, but the reporter probes are exonuclease resistant (after they are joined together). In these embodiments, the method further includes treating the sample with an exonuclease to remove unligated oligonucleotides and other single-stranded nucleic acids. As indicated, the term "release" is intended to refer to a cleavage or dehybridization event that produces a reporter probe that can be transferred to a support.

[0070] In some embodiments, the method may include contacting a tissue sample with an antibody-oligonucleotide conjugate under conditions where the antibody binds to a site in or on the sample, and the method may further include releasing the oligonucleotide or an extension product of the oligonucleotide from the conjugated antibody to produce a reporter probe. In any embodiment, the releasing may be performed by contacting the biological sample with the support while the biological sample faces the support and then heating the sample.

[0071] In some embodiments, the reporter probe is generated via a ligation, gap-fill or primer extension reaction.

[0072] In some embodiments, the analyzing step may be performed by microscopy.In these embodiments, the method may include directly or indirectly hybridizing one or more labeled oligonucleotides to a reporter probe, and then analyzing the binding pattern of the labeled oligonucleotides by microscopy.In some embodiments, the labeled probe hybridizes to the ligation bond or the extension bond in the reporter probe.

[0073] In some embodiments, the method may comprise: (a) performing a proximity assay in situ on one or more pairs of binding agent-oligonucleotide conjugates bound to the sample to generate proximity assay reaction products; (b) transferring the nucleic acid reaction products into or onto a support so as to preserve the spatial relationship of the proximity assay reaction products in the sample; and (c) detecting the proximity assay reaction products in or on the support.

[0074] As described above and below, the proximity assay can include ligation, primer extension, gap-fill / ligation, or a hybrid thereof, and can transfer either the initial or "first" product or the complementary sequence of the first product (which can be generated by ligating two reporter oligonucleotides together using the initial product as a template) to the support. For example, in one non-limiting embodiment, the method can include performing a proximity assay in situ on one or more pairs of binder-oligonucleotide conjugates bound to the sample to generate a first product, and transferring the first product to the support. The first product can be generated via a proximity ligation assay or a proximity extension assay.

[0075] The proximity ligation assay may include templated ligation of the oligonucleotides of the binder-oligonucleotide conjugate using a splint. The ligation may or may not include extending the 3' end of one of the oligonucleotides to make it adjacent to the 5' end of the other oligonucleotide. The proximity extension assay may include hybridizing the complementary 3' ends of the oligonucleotides of the binder-oligonucleotide conjugate and extending the 3' end of the oligonucleotide using the other hybridized oligonucleotide as a template.

[0076] The first product may be released, eg, cleaved or dehybridized, from the binding agent prior to transfer to the support.

[0077] In some cases, the method may comprise step (a) comprising: (i) ligating and / or extending the oligonucleotides of the binder-oligonucleotide conjugate together to produce a first product; and (ii) ligating together a pair of tailed detection oligonucleotides using the first product as a template to produce a second product, wherein (i) and (ii) are performed sequentially or in the same step; and step (b) comprises transferring the second product onto a support.

[0078] An example of one embodiment of the method is shown in FIG. 3. As shown in FIG. 3, the method may include binding a tissue section with a plurality of binder-oligonucleotide conjugates and performing a proximity assay in situ on the bound conjugates. As shown, the binder portion of the conjugate may be an antibody. However, in other embodiments, the binder may be an aptamer or an oligonucleotide probe. The proximity assay may be performed using a variety of different methods, such as a proximity ligation assay (where the ends of the oligonucleotides in the conjugates that bind to adjacent sites are ligated to each other, resulting in a first product), or a proximity extension assay (where one or both oligonucleotides are extended using the other as a template, resulting in a first product). In either case, the first products may be released from the binders to which they are tethered and then transferred to a support as proximity assay reaction products in step (c). In these embodiments, the proximity assay reaction products transferred to the support in step (c) are the first products. In other cases, the first product can be used as a splint to ligate a pair of tailed detection oligonucleotides together to create a second product. In these embodiments, the proximity assay reaction products transferred to the support in step (c) are the second products. As shown, the proximity assay reaction products are transferred to the support so as to preserve their spatial relationship in the xy plane, and then the tissue section is removed from the support. In this method, the proximity assay reaction products are tethered to the support and then detected on the support, for example, by hybridizing (directly or indirectly) labeled probes to the tethered proximity assay reaction products while placing them on the support and analyzing the label pattern by microscopy. The support may be a planar substrate, such as a slide (which may be coated), or a three-dimensional substrate, such as a gel. When the substrate is a planar substrate, the proximity assay reaction products are on the substrate. When the substrate is a three-dimensional substrate, the proximity assay reaction products are in the substrate.

[0079] FIG. 4 shows an example of how a proximity assay can be performed. As mentioned above, a proximity assay can be performed in many different ways. In the embodiment shown, the oligonucleotides of the two binder-oligonucleotide conjugates that are bound to the proximal sites can be ligated together to generate a first product. This ligation reaction can be supported, but need not be. This embodiment of the method may include ligating together a pair of tailed reporter oligonucleotides using the first product as a template to generate a proximity assay reaction product. In these embodiments, the proximity assay reaction product is transferred to a support in step (c).

[0080] FIG. 5 illustrates an exemplary detection method, the details of which are provided in more detail below.

[0081] The sites that generate a signal on the support correspond to sites in the planar biological sample. Thus, analysis of sites where nucleic acid reaction products are bound on the support can be mapped to sites in the tissue sample. Thus, among other things, the locations of different nucleic acid reaction products in or on the support can be used to 1) determine where a particular protein or proteins are located, for example, using antibodies that bind to different sites on the same protein; 2) identify where protein-protein interactions occur, for example, using antibodies that bind to different proteins; and / or 3) determine post-translational modifications, for example, using one antibody that binds to a modified site in the protein and another antibody that binds to a different or unmodified site in the protein. Other uses (e.g., mapping RNA, protein-RNA interactions, protein-DNA interactions, etc.) are readily apparent.

[0082] The method of the present invention does not include any nucleic acid amplification step (e.g., PCR or rolling circle amplification), and the reporter probes / reaction products are transferred en bloc, i.e., together, simultaneously, from the sample to the support, without transferring molecules from one region of the sample, then another region of the sample, etc. The method does not include sequencing, and does not utilize oligonucleotides with spatial barcodes, i.e., sequences corresponding to coordinates in the xy plane, or arrays thereof (each element of the array has a sequence that identifies its location on the array). No proximity assay is performed on the transferred molecules (support or otherwise). Rather, detection is by hybridization of a labeled probe to the transferred molecules, and imaging, e.g., by microscopy. For clarity, the planar sample used in the method is not a liquid sample. Most commonly (though not always), the sample is a tissue section. None of the reporter probes / reaction products are circular. Rather, they are linear and often have an affinity group at one end and a protected other end, so that they are protected from exonuclease degradation and can be attached to the support. For clarity, molecules (e.g., RNA) that are endogenous to the sample (i.e., "biological molecules") are not transferred to the support or analyzed on the support. Rather, synthetically produced molecules (e.g., oligonucleotides, or their cleavage, ligation, or extension products) are transferred and analyzed.

[0083] In exemplary embodiments, the first step of the method may be to bind together a pair of oligonucleotides. In these embodiments, one of the oligonucleotides contains a biotin group at one end, and the other contains a modification at the other end that makes it exonuclease resistant. In the unligated form, both oligonucleotides are exonuclease sensitive. However, when they are ligated together, the ligation product is exonuclease resistant. This ligation product is transferred to a support coated with streptavidin or avidin, to which the product is attached. To reduce background, the sample (after ligation) may be treated with one or more exonucleases and / or the substrate (after the product is transferred onto the support) may be treated with one or more exonucleases.

[0084] In any embodiment, the method may further comprise using a DNA modifying enzyme, e.g., a ligase, a kinase, an exonuclease, a terminal transferase, a deaminase, a deglycosylase, a methylase, a phosphatase, to modify the oligonucleotide, its extension product, or a reporter molecule, and optionally conjugating it in situ during or after the transfer to a chemical moiety or a linking agent, etc.

[0085] Binder The binding agent may be an antibody or an antigen-binding fragment of an antibody, such as Fab, Fv, scFv, F(ab')2, and Fd. The binding agent may also be a scaffold protein developed for affinity, such as an affibody or similar affinity protein.

[0086] In some cases, the antibody against the antigen is a monoclonal antibody.

[0087] In one embodiment, the antibody against the antigen is a split polyclonal antibody.The split polyclonal antibody is produced by raising polyclonal antiserum against the antigen and splitting the antiserum into two parts.An oligonucleotide having a specific sequence is conjugated to the antibody against the antigen in one part of the polyclonal antiserum, and an oligonucleotide having a different specific sequence is conjugated to the antibody against the antigen in the other part.

[0088] The binding agent may also be an aptamer that specifically binds to a protein, carbohydrate, or small molecule.

[0089] Furthermore, the binder can be an oligonucleotide that specifically binds to a target sequence, for example, a specific target sequence in RNA or DNA. The oligonucleotide binder can specifically bind to a target RNA, such as messenger RNA (mRNA), transfer RNA (tRNA), or ribosomal RNA (rRNA). The oligonucleotide binder can also specifically bind to a target DNA, such as chromosomal DNA or extrachromosomal DNA. The extrachromosomal DNA can be organelle DNA, such as mitochondrial DNA or chloroplast DNA.

[0090] Binding target site Binding agents are capable of specifically binding to binding target sites, such as sites on proteins, RNA, DNA, carbohydrates, proteoglycans, lipids, and other biomolecules.

[0091] The binding sites of the binding agents can be on the same protein or on different proteins. For example, the binding agents can bind to different epitopes in the same protein. In some cases, one of the binding agents used in the proximity assay can bind to a site in a protein that is not post-translationally modified, while the other binding agent can specifically bind to the same protein at a site that is post-translationally modified. Post-translational modifications can be, for example, phosphorylation, glycosylation, ubiquitination, nitrosylation, methylation, acetylation, and lipidation, although many other types of post-translational modifications are known.

[0092] As noted above, the RNA binding target can be any type of RNA, including mRNA, tRNA, non-coding RNA, or rRNA.

[0093] The DNA binding target may also be chromosomal or extrachromosomal DNA. Extrachromosomal DNA may be organelle DNA, such as mitochondrial DNA or chloroplast DNA.

[0094] In some cases, oligonucleotide probes can be used to detect mutations in DNA. In such cases, target DNA is converted to single-stranded without destroying tissue and other molecules. For example, specific targets in DNA molecules can be converted to single-stranded state by using nicking enzymes or CRISPR-based targeting. The single-stranded DNA thus generated can be digested, for example, with 3' or 5' specific exonuclease, leaving only one strand of target DNA for mutation analysis.

[0095] The target molecule may also be of viral or bacterial origin.

[0096] Proximity assay As noted above and below, the proximity assay can be performed in a variety of different ways, which can include ligation, extension, or gap-fill / ligation, etc. In some cases (as shown in FIG. 4), the method can include step (a) comprising (i) ligating and / or extending oligonucleotides of a binder-oligonucleotide conjugate together to generate a first product, and (ii) ligating a pair of tailed reporter oligonucleotides together using the first product as a template to generate a proximity assay reaction product, where (i) and (ii) are performed sequentially or in the same step. In other embodiments, step (a) can include ligating and / or extending oligonucleotides of a binder-oligonucleotide conjugate to generate a proximity assay reaction product. In these embodiments, the proximity assay reaction product can be cleaved from the binder prior to transfer to the support.

[0097] Proximity ligation assay In some embodiments, step (a) comprises PLA. Any suitable method can be used to ligate the oligonucleotides conjugated to the binder-oligonucleotide conjugate in PLA. For example, the oligonucleotides from the binder-oligonucleotide conjugate can be ligated together via non-templated ligation of the single-stranded end of nucleic acid, non-templated ligation of the double-stranded end of nucleic acid, templated ligation using a splint, or overhang-mediated ligation of double-stranded nucleic acid using complementary overhangs.

[0098] In one embodiment, PLA involves contacting a biological sample with a first target-specific binding agent-oligonucleotide conjugate comprising a first target oligonucleotide and a second target-specific binding agent-oligonucleotide conjugate comprising a second target oligonucleotide. Multiple pairs of first and second target-specific binding agent-oligonucleotide conjugates can also be used in a multiplex reaction.

[0099] In a pair of target-specific binding agent-oligonucleotide conjugates, the first target oligonucleotide has a free 3' end and includes from the 5' end one or more barcodes specific to the first target and a first splint hybridization region, and the second target oligonucleotide has a free 5' end and includes from the 3' end one or more barcodes specific to the second target and a second splint hybridization region.

[0100] Upon binding of the pair of target-specific binding agent-oligonucleotide conjugates to their corresponding target sites, the biological sample is contacted with a splint oligonucleotide that hybridizes at its two ends to a first and second oligonucleotide that are brought into proximity with each other via binding of the first target-specific binding agent to the first target site and the second target-specific binding agent to the second target site.

[0101] A splint oligonucleotide can bring together the 5' and 3' ends of a first and second oligonucleotide, in which case the two oligonucleotides can be ligated to generate a ligated oligonucleotide. A splint oligonucleotide can be designed such that the 3' end of one oligonucleotide is not adjacent to the 5' end of the other oligonucleotide. In such a case, the 3' end can be extended, for example, using a polymerase to extend the 3' end of the first oligonucleotide toward the 5' end of the second oligonucleotide. The two oligonucleotides can then be ligated to generate a ligated oligonucleotide.

[0102] Thus, in some cases, a ligation assay can include (i) labeling a planar biological sample with multiple pairs of binder-oligonucleotide conjugates; (ii) hybridizing a splint oligonucleotide to the sample after (i), where the splint oligonucleotide hybridizes to ends of oligonucleotides in different conjugates; and (iii) ligating together the ends of any oligonucleotides in the conjugates hybridized to the same splint oligonucleotide to generate a nucleic acid reaction product.

[0103] In some embodiments, the ligation assay may involve ligating the oligonucleotides of the binder-oligonucleotide conjugates via templated or non-templated ligation of single-stranded ends of the oligonucleotides, non-templated ligation of double-stranded ends of the oligonucleotides, or overhang-mediated ligation of double-stranded oligonucleotides using complementary overhangs. Templated ligation embodiments may be achieved using a ligation splint, where the splint is designed such that the 3' end of a first oligonucleotide of a first binder-oligonucleotide conjugate is adjacent to the 5' end of a second oligonucleotide of a second binder-oligonucleotide conjugate, and the method includes ligating the 5' and 3' ends of the first and second oligonucleotides.

[0104] Oligonucleotides can also be joined to each other via a gap-fill / ligation reaction, in which two oligonucleotides hybridize to opposite ends of a template, the gap is filled by polymerization, and the nick is sealed by ligation.

[0105] Many variations of these assays are known. For example, in some embodiments, "unfolded" probes can be used. See, for example, Klaesson et al. (Sci Rep8,5400 (2018)).

[0106] Proximity extension assay (PEA) In some embodiments, step (a) comprises PEA. Any suitable method can be used to generate nucleic acid reaction products from oligonucleotides from binder-oligonucleotide conjugates. In one embodiment, PEA comprises contacting a biological sample with a first target-specific binder-oligonucleotide conjugate comprising a first oligonucleotide and a second target-specific binder-oligonucleotide conjugate comprising a second oligonucleotide. Multiple pairs of the first and second target-specific binder-oligonucleotide conjugates can also be used in a multiplex reaction.

[0107] In a pair of specific binding agent-oligonucleotide conjugates, the free 3' ends of the first and second oligonucleotides have sequences complementary to each other, and thus the free ends hybridize to each other. These free 3' ends can be extended, for example, using a polymerase, to create a double-stranded oligonucleotide that contains the sequences of both the first and second oligonucleotides.

[0108] Therefore, in some cases, PEA may: (i) labeling a planar biological sample with pairs of binding agent-oligonucleotide conjugates; (ii) hybridizing complementary 3' ends of the oligonucleotides and extending the 3' ends of the oligonucleotides using the other hybridized oligonucleotides as templates to produce a nucleic acid reaction product.

[0109] Hybrid Assay In some embodiments, multiple combinations of interactions are analyzed using the methods disclosed herein, and combinations of PLA and PEA are used to generate nucleic acid reaction products.

[0110] For example, a nucleic acid reaction product is generated from a specific interaction with PLA and a nucleic acid reaction product is generated from a specific other interaction with PEA. Specific details of PLA and PEA are described above and can be used in the hybrid methods contemplated herein.

[0111] RNA detection using ligation assays In some cases, the method includes detecting RNA using a ligation assay. In particular, the reporter polynucleotide can be designed to hybridize with a specific sequence in the target RNA. The probe can have a tail that contains a barcode. In some cases, the oligonucleotide probe includes DNA nucleotides, except at the ligation site where the oligonucleotide includes RNA nucleotides. Thus, the oligonucleotide probe can be a hybrid of DNA and RNA nucleotides. Alternatively, the reporter polynucleotide can include a hairpin structure such that the oligonucleotides ligate to each other when they are brought together via the target RNA.

[0112] Proximity assays using three or more binders In some cases, the proximity assay is performed with three or more binding agents. Examples of such assays are described in Schallmeine et al., (2007), Nat. Methods.; 4(2): 135-7.

[0113] In some cases, three binder-oligonucleotide conjugates are used, the first binder-oligonucleotide conjugate is conjugated to the first oligonucleotide, the second binder-oligonucleotide conjugate is conjugated to the second oligonucleotide, and the third binder-oligonucleotide conjugate is conjugated to the splint oligonucleotide. When the three oligonucleotides are brought into proximity with each other through the binding of the three binders to the proximity binding targets, the splint oligonucleotide hybridizes to the first and second oligonucleotides, which can be ligated to generate a nucleic acid reaction product. Thus, the generation of a nucleic acid reaction product indicates that the oligonucleotide is conjugated to a binder that is bound to the proximity site.

[0114] Reporter probes In some embodiments, the first product, i.e., the nucleic acid generated from the initial primer extension, ligation, or gap fill / ligation, may be used as a ligation template or ("sprint") to ligate two or more other oligonucleotides (referred to herein as "reporter oligonucleotides") together to generate a reporter probe. In these embodiments, the reporter probe is a proximity assay reaction product that is transferred to a substrate. An example of this embodiment is shown in Figure 4. Alternatively, the reporter probe may be made by hybridization to oligonucleotides that are adjacent to each other without linking the first oligonucleotides together (see, e.g., Figure 6B).

[0115] In these embodiments, the first product is used as a template to ligate together a pair of reporter oligonucleotides (a "first" reporter oligonucleotide and a "second" reporter oligonucleotide) to generate a proximity assay reaction product. As shown, the reporter oligonucleotides can be "tailed" such that they contain a first sequence that hybridizes to the first product and a tail sequence that does not hybridize to the first product. As shown, one of the reporter oligonucleotides has a 5' tail and the other has a 3' tail. The tails can be of any suitable length (e.g., up to 20-200) and can be used for detection after the proximity assay reaction products are transferred to a support.

[0116] One or more of the tails may contain modifications. For example, the tail may contain binding members, reactive groups, or moieties that facilitate the transfer of the reporter probe to the support, the anchoring of the probe on or in the support, or modifications to protect it from exonuclease activity. For example, in some embodiments, one of the ends of the reporter oligonucleotide may contain a chemical property for attaching the product to a substrate such as a glass slide. These modifications include, but are not limited to, hydrazide groups (I-LINKER™), amine groups (e.g., amines covalently attached to activated carboxylate groups or succinimidyl esters), thiol groups (e.g., thiol groups covalently attached via alkylating agents such as iodoacetamide or maleimide), acryl groups that may be attached via thioethers (ACRYDITE™), digoxigenin NHS ester groups, cholesterol-TEG groups, or biotin, and the like. Such groups can be tethered to glass slides using the following chemistries: NH2-modified oligonucleotides are attached to epoxysilane or isothiocyanate-coated glass slides, succinylated oligonucleotides are attached to aminophenyl or aminopropyl-derivatized glass slides, disulfide-modified oligonucleotides are attached to mercaptosilanized glass slides, and hydrazide oligonucleotides are attached to aldehyde or epoxide-modified glass slides. Click-reactive groups can be used in several situations. In embodiments, nucleic acids can be immobilized to supports by biotin-avidin / streptavidin / neutravidin interactions, where the nucleic acid contains a biotin moiety and the support is coated with avidin, streptavidin, or neutravidin.

[0117] As will be apparent, the reporter oligonucleotides can be designed such that their ends are abutting when they are hybridized to the first product. Alternatively, the ends need not be abutting and gaps can be filled and sealed.

[0118] In some embodiments, the reporter oligonucleotide may be part of an oligonucleotide that is conjugated to a binder and cleaved and ligated together during a proximity assay. For example, the oligonucleotide conjugated to the binder may contain a hairpin or loop that contains more uracil (or a restriction site) that allows the reporter oligonucleotide and / or the reporter probe to be cleaved from the oligonucleotide during the reaction (see, for example, Klaesson et al. (Sci Rep 2018 8,5400)).

[0119] In another embodiment, the reporter oligonucleotide can be pre-hybridized to the oligonucleotide that is conjugated to the binder, which also avoids adding the reporter oligonucleotide separately. Furthermore, the resulting DNA complex can also be designed to have a region that can be cut or removed to expose a single-stranded sequence that can be used to bind the binder and / or the detection oligonucleotide by ligation using splint-mediated ligation or overhang-mediated ligation, thereby eliminating the presence of single-stranded regions during incubation and binding of the binder, and also ensuring that the detection oligonucleotide is present on each binder to increase efficiency. Using two separate oligonucleotides can increase oligonucleotide quality by reducing the length of each oligonucleotide that needs to be synthesized and reducing the challenges of synthesizing long ssDNA, especially when the oligonucleotide is modified at a specific site.

[0120] RNA detection using reporter polynucleotides In some cases, the RNA target from planar biological sample is directly used as a template to generate reporter polynucleotide, i.e., no proximity assay is performed to generate nucleic acid reaction products, but the RNA target is used as a template to generate reporter polynucleotide.For example, the first reporter probe and the second reporter probe can be designed such that when binding to the RNA target, the 5'-end and the 3'-end of the first and second reporter probe are close to each other, and in this case, the two reporter probes can be ligated to generate reporter polynucleotide.

[0121] The first and second reporter probes can also be designed such that, upon binding to an RNA target, the 3' end of one reporter probe is not adjacent to the 5' end of the other reporter probe. In such a case, the 3' end can be extended, for example, using a polymerase to bring the 5' and 3' ends of the first and second reporter probes together, which can then be ligated to generate a reporter polynucleotide.

[0122] Exonuclease digestion In any embodiment, the method may include digestion with one or more exonucleases (e.g., both exonuclease I and exonuclease III, but one or more other exonucleases, such as exonuclease T, exonuclease V, exonuclease VII, T5 exonuclease or T7 exonuclease, may optionally be used instead) to remove unligated reporter oligonucleotides and other single-stranded nucleic acids. This digestion may be performed at any time after the initial proximity assay reaction products are generated. For example, digestion may be performed in situ during or after the transfer step. In these embodiments, the oligonucleotides used in the proximity assay (e.g., the first oligonucleotide attached to the binder, or the reporter oligonucleotide) may be designed to generate exonuclease resistant products, which allows these products to survive the exonuclease step. For example, if reporter oligonucleotides are used, one of the reporter oligonucleotides may have a protected 3' end, for example, and / or the other of the reporter oligonucleotides may have a protected 5' end, for example. The oligonucleotides can be made exonuclease resistant by the addition of an exonuclease resistant linkage, such as a phosphorothioate linkage, although other linkages can be used. In an alternative embodiment, the reporter oligonucleotides and other single-stranded DNA molecules can be removed by washing at a temperature below the Tm of the template duplex that is the proximity assay reaction product.

[0123] Increased signal with redundant probe sets and decreased signal with defective ligation events To generate more signals from rare binding events, several nucleic acid reaction products can be generated from each binding event. For protein targets, this can be achieved using binding agents that are each conjugated to several oligonucleotides. This then generates several assay products in a proximity assay. For RNA and DNA targets, multiple probe sets can be designed to target each RNA molecule or DNA locus, so that each target generates many nucleic acid reaction products. At least two or more, or at least five or more, or at least ten or more nucleic acids can be used per binding agent that is directly or indirectly associated with the binding agent. At least two or more, or at least five or more, or at least ten or more, or at least twenty or more probe pairs can be used to target RNA or DNA sequences.

[0124] The number of probe sets used can be calibrated using the expression level of target molecules to balance the number of reporter molecules made between different targets.Also, the probe designed to analyze targets that are present in very high abundance can be designed to have a fraction of probes that are defective and cannot make reporter molecules.This can be used to reduce the signal from, for example, highly expressed proteins or RNAs, which would otherwise require a very large amount of detection area on the support.

[0125] Transfer of nucleic acid reaction products to a solid support The nucleic acid reaction products generated in a proximity assay or via a reporter probe can be transferred to a solid support. In certain embodiments, the generated nucleic acid reaction products are cleaved or otherwise separated from the corresponding binding agent and then transferred to the support. The transfer of the nucleic acid reaction products onto the support is performed in a manner that preserves the spatial relationship of the nucleic acid reaction products in the sample.

[0126] In some embodiments, a nucleic acid reaction product is generated having a first binding member of a specific binding pair, and the nucleic acid reaction product is transferred to a support that contains a second binding member of the specific binding pair. Thus, specific binding between the first and second binding members of the specific binding pair immobilizes the nucleic acid reaction product on the support. In one embodiment, the specific binding pair comprises biotin and streptavidin.

[0127] Planar support In some embodiments, the support can be planar. The planar support can be the same solid support on which the tissue section is immobilized. In this case, the bond between the nucleic acid reaction product and the solid support is inducible. One example of such an inducible reaction uses click chemistry, which requires an inducer such as copper to create a covalent bond. In another example, the nucleic acid reaction product is ligated to an oligonucleotide immobilized on a solid support. Such ligation can be performed using a template splint that brings together the ends of the nucleic acid reaction product and the oligonucleotide immobilized on the solid support.

[0128] Alternatively, another planar support can be used to transfer the reporter polynucleotide from the tissue. The transfer of the reporter polynucleotide from the tissue to the planar support can be accelerated using electrophoresis. In some embodiments, electrostatic interactions (e.g., between the molecule to be transferred and a positively charged surface (in the case of a slide coated with polylysine)) can facilitate the transfer of the molecule to the support. In some embodiments, the support can be coated with avidin or streptavidin, which binds to the biotinylated reporter molecule. In some cases, magnetism is used to accelerate the transfer using magnetic or paramagnetic beads associated with the reporter molecule.

[0129] In one embodiment, the planar support to which the nucleic acid reaction products from the tissue are transferred does not have oligonucleotides attached thereto, and thus the nucleic acid reaction products are transferred to and attached to the planar support through means other than by oligonucleotides.

[0130] As mentioned above, one such method of attaching a nucleic acid reaction product to a planar support without using oligonucleotides involves generating a copied nucleic acid reaction product or reporter polynucleotide with a first binding member of a specific binding pair. The reporter polynucleotide is transferred to the planar support, which includes a second binding member of the specific binding pair. Thus, specific binding between the first and second binding members of the specific binding pair immobilizes the nucleic acid reaction product on the planar support. For example, the specific binding pair includes biotin and streptavidin.

[0131] A specific additional method for attaching a nucleic acid reaction product to a planar support without the use of oligonucleotides involves modifying the planar support to provide specific functional groups that react and form bonds with a nucleic acid reaction product that contains other functional groups that react with functional groups on the planar support.

[0132] Further such methods of attaching nucleic acid reaction products to planar supports without the use of oligonucleotides include modifying oligonucleotides to contain amino groups that react with epoxysilane or isothiocyanate coated planar supports, modifying oligonucleotides to contain succinic acid groups that react with aminophenyl or aminopropyl derivatized planar supports, modifying oligonucleotides to contain disulfide groups that react with mercaptosilanized solid supports, modifying oligonucleotides to contain hydrazide groups that react with aldehyde or epoxide group containing solid supports, and attaching oligonucleotides to polylysine containing planar supports. Additionally, any further suitable protocol for attaching nucleic acid reaction products to planar supports without the use of oligonucleotides can be used.

[0133] Tissue removal In any embodiment, the methods disclosed herein include removing the planar biological sample from the support to leave the nucleic acid reaction products on or in the support (FIGS. 1 and 3).

[0134] The planar biological sample can be removed from the support in any suitable manner. For example, the substrate, such as a glass slide, on which the planar biological sample is placed can be simply removed from the support. Since the nucleic acid reaction product is bound to the support either covalently or non-covalently, the nucleic acid reaction product remains attached to the support, but the remaining tissue is removed from the support.

[0135] Any remaining residues of the biological sample can be removed by enzymatic action. For example, the support can be treated with an enzyme that degrades biomolecules other than polynucleotides, thereby removing only biomolecules other than nucleic acids. Furthermore, if the nucleic acid reaction products include DNA, the support can be treated with RNase to remove contaminating RNA.

[0136] Labeling and Detection In some cases, the methods disclosed herein include detecting the location of the nucleic acid reaction products on the support, preferably as individual molecules, such detection includes detectably binding a labeled probe to the nucleic acid reaction products on or in the support and detecting the labeled probe to determine the distribution of the nucleic acid reaction products on or in the support.

[0137] In one embodiment, detecting a nucleic acid reaction product on or in a support comprises: (i) labeling a nucleic acid reaction product on or in a support; (ii) imaging the support to generate an image of the sites where the nucleic acid reaction product is bound to the support.

[0138] In some embodiments, the proximity assay reaction products are detected in or on the support by hybridization to a defined nucleic acid structure composed of a predetermined number of oligonucleotides and a predetermined number of labeled oligonucleotides. In these embodiments, the structure may be nucleated by at least two hybridization events to the proximity assay reaction products. In these embodiments, the at least two hybridization events include a first hybridization to a first sequence in the proximity assay reaction products and a second hybridization to a second sequence in the proximity assay reaction products. An example is a nucleic acid structure as shown in FIG. 5.

[0139] In these embodiments, to quantify the nucleic acid reaction products as single molecules, it may be advantageous to incorporate a defined number of detection labels per nucleic acid reaction product in order to obtain a reproducible and stable signal from every molecule. Approaches such as RCA or other clonal amplification strategies may be used to detect molecules transferred onto a planar support, but they usually do not incorporate a defined number of labels per molecule and may create uneven signals from different molecules, causing crowding when the signal is large and undetectable signals when the signal is weak. By designing programmable hybridization, a specific number of hybridization events occur for each detected target, resulting in a predefined specific number of oligonucleotides and labels that are incorporated into each formed nucleic acid structure. These structures may be advantageously designed such that two or more initial independent hybridization events to the target are required for the nucleation of the nucleic acid structure to be detected. Once the initial hybridization to the nucleic acid reaction product occurs, they stably attract the hybridization and formation of the remaining oligonucleotides. The hybridization events that form the nucleic acid structure may, in some cases, be advantageously separated into two or more steps, since it may be difficult to design the oligonucleotides such that the entire structure does not form spontaneously when all the oligonucleotides are present in the same solution.

[0140] The detection reactions are also advantageously designed so that a single label or label structure present at each step does not generate a detectable signal if the label or label structure adsorbs non-specifically to a surface.

[0141] In any embodiment, the molecules transferred to the support may contain sequences complementary to sequences in the probe system used. These sequences may be in the tail of a reporter oligonucleotide (which becomes a reporter probe) or may be incorporated into an oligonucleotide that is conjugated to a binding agent, for example.

[0142] Each of these sequences may have multiple binding sites for the probe system, thereby allowing the support to be interrogated by multiple rounds of hybridization, reading, and signal removal. Such sequences may be referred to herein as "barcode" sequences. In some embodiments, the identity of the reporter molecule in or on the support may be determined by reading the code corresponding to whether the product hybridizes or does not hybridize each probe of the set of probes, as described, for example, in Goransson et al. (Nucl.Acids Res.2009 37:e7), Moffitt et al. (Methods Enzymol.2016 572:1-49) and Moffit et al. (Proc.Natl.Acad.Sci.2016 113:11046-51).

[0143] Thus, in some cases, the method may include determining which combinations of probes bind to reporter molecules. Such detection may be mediated by specific detection and labeling probes that specifically bind to these sequences. The design and detection of labeling probes that bind to specific barcode sequences is well known in the art, and such embodiments are within the scope of the present invention.

[0144] In some cases, specific detection probes are added in multiple cycles, labeling a different barcode(s) in each cycle, thereby detecting the binary string of barcodes present in each nucleic acid reaction product. Each cycle can include labeling, washing, imaging, and removal of the detection probe before the next cycle begins.

[0145] DNA Origami In some cases, DNA origami is used to label and detect nucleic acid reaction products on planar surfaces.

[0146] As used herein, "DNA origami" refers to the mixing and sequence-dependent folding of DNA molecules to create two-dimensional and three-dimensional shapes. The two-dimensional and three-dimensional shapes are at the nanoscale level. The shapes are generated based on the sequence of mixed DNA molecules that hybridize with each other in a specific way to form two-dimensional or three-dimensional structures.

[0147] Thus, in some cases, the bridging probes, labeling probes, and / or detection probes are generated such that when mixed together, they form two- or three-dimensional structures that specifically bind to nucleic acid reaction products on a surface.

[0148] DNA origami structures can be advantageously designed such that colocalization by hybridization and / or ligation to the barcodes of two or more seeding oligonucleotides, optionally introduced in a separate initial step, is required to initiate the formation of the DNA origami structure and to avoid non-specific signal generation created, for example, by background adsorption of oligonucleotides.

[0149] Detection System In some embodiments, the detection system can be designed such that at each cycle, pairs of oligonucleotides in the detection system hybridize cooperatively to their respective barcode sequences in the transferred reporter molecules. An example of such labeling and detection is shown in FIG. 5. In this example, hybridization of the bridging detection probe to the barcode is stabilized by a relatively short (e.g., 4-10 bp) complementary sequence at the end of the bridging detection probe (FIG. 5). Alternatively, the complex can be stabilized by ligating the ends of the bridging probe together.

[0150] As shown in FIG. 5, in some embodiments, the method may include hybridizing the support-tethered proximity assay reaction products with a pair of cross-linking probes comprising a first cross-linking probe and a second cross-linking probe, each cross-linking probe comprising a barcode hybridization region that hybridizes to a portion of a barcode.

[0151] In some cases, the first crosslinking probe further comprises a first barcode indicator region (i.e., a region that does not hybridize to the barcode sequence) and the second crosslinking probe further comprises a second barcode indicator region (i.e., another region that does not hybridize to the barcode sequence), and hybridization of the first and second crosslinking probes to the barcode brings the first and second barcode indicator regions into close proximity to each other.

[0152] In these embodiments, after the cross-linking probe is hybridized to the barcode, the remainder of the detection system (which may be composed of a labeling probe and a detection probe, as shown in FIG. 5) may be added sequentially or together. As shown, the detection system may include a labeling probe that hybridizes to both the first and second indicator regions, and a detection probe that hybridizes to the labeling probe. The detection probe may be pre-hybridized to the labeling probe, but this is not required. As shown in FIG. 5, the labeling probe hybridizes to a pair of cross-linking probes. Thus, in some cases, detecting the cross-linking probe hybridized to the barcode may include hybridizing a labeling probe to the barcode indicator region, where the labeling probe includes a first labeling region that hybridizes to the first barcode indicator region and a second labeling region that hybridizes to the second barcode indicator region. As shown, the detection probe (which may be labeled with a fluorophore) is hybridized to the labeling probe.

[0153] As shown, multiple detection probes, e.g., 5-10, up to 20 or more, can be hybridized to one pair of labeled probes. Considering that a pair of bridging probes is attached to the proximity assay reaction product, several detection probes can be hybridized to one labeled probe to record a signal against background (Figure 5). This design ensures that the signal generation specificity is maintained and the signal is uniform from one hybridization event to another. Individual bridging probes do not create background when they attach to a surface, and individual labeled probes may not create enough signal to create a signal above background. Thus, a detectable signal can only be generated when multiple labeled probes are hybridized to a pair of bridging probes. Multiple labels with different fluorophores can be used so that multiple barcodes can be detected in one labeling cycle. The hybridization chemistry is designed to have a defined number of fluorophores for each target molecule.

[0154] Thus, by repeating the cycle of labeling and detection, the locations can be determined for multiple barcodes on the support. Based on the locations of the barcodes on the support and known information about the binding agents conjugated to oligonucleotides containing those barcodes, a map of binding targets in a planar biological sample can be generated.

[0155] Mapping nucleic acid reaction products onto planar biological samples In some embodiments, in addition to detecting the position of the barcode and thus creating a map of the binding targets in the planar biological sample, the method further comprises generating an optical image of the planar biological sample. The optical image of the planar biological sample can be generated by staining the sample with a microscopic stain. The image of the sample can then be compared or overlaid with the map of the binding targets in the planar biological sample. Such an overlay can be useful in determining the distribution of a particular biomolecule (i.e., the binding target of a binding agent used in a proximity assay) in different regions of the biological sample.

[0156] The sample may be stained using a cytological stain before or after performing the above methods. In these embodiments, the stain may be, for example, phalloidin, gadodiamide, acridine orange, bismarck brown, vermin, Coomassie blue, bresil violet, bristol violet, DAPI, hematoxylin, eosin, ethidium bromide, acid fuchsin, hematoxylin, Hoechst stain, iodine, malachite green, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide (formal name: osmium(VIII) oxide), or osmium tetraoxide (formal name: osmium(VIII) oxide). tetraoxide), rhodamine, safranine, phosphotungstic acid, osmium tetroxide, ruthenium tetroxide, ammonium molybdate, cadmium iodide, carbohydrazide, ferric chloride, hexamine, indium trichloride, lanthanum nitrate, lead acetate, lead citrate, lead(II) nitrate, periodic acid, phosphomolybdic acid, potassium ferricyanide, potassium ferrocyanide, ruthenium red, silver nitrate, silver proteinate, sodium chloroaurate(III), thallium nitrate, thiosemicarbazide, uranyl acetate, uranyl nitrate, vanadyl sulfate, or any derivative thereof. Staining may be specific for any feature of interest, such as a single protein or classes of proteins, phospholipids, DNA (e.g., double-stranded DNA, single-stranded DNA), RNA, organelles (e.g., cell membrane, mitochondria, endoplasmic reticulum, Golgi apparatus, nuclear envelope, etc.), cell compartments (e.g., cytosol, nuclear fraction, etc.). Staining may improve contrast or imaging of intracellular or extracellular structures. In some embodiments, samples may be stained with hematoxylin and eosin (H&E).

[0157] Method multiplexing In some cases, the methods disclosed herein can be used to analyze multiple target binding sites, such as multiple RNAs, proteins, or multiple molecular interactions.In such embodiments, multiple binding agents are conjugated with oligonucleotides having specific barcodes.Depending on the distribution of multiple binding targets, different binding agents having oligonucleotides having specific barcodes will be combined with other binding agents having oligonucleotides having other specific barcodes.

[0158] Creation and detection of a nucleic acid reaction product containing a combination of two specific barcodes at a particular location on the support indicates that the binding sites of a binding agent having the two specific barcodes are located at corresponding locations in the planar biological sample.

[0159] In some embodiments, the proximity assay can be performed using multiple pairs of binder-oligonucleotide conjugates (e.g., at least 4 pairs, at least 10 pairs, or at least 50 pairs). The proximity assay can be designed so that each conjugate can generate reaction products with one other conjugate, with some but not all of the multiple conjugates, or with all of the other conjugates. For example, a ligation splint can be designed to bind a specific pair of 3' and 5' binders, e.g., to examine a specific protein or interaction, can be designed to bind a specific set of 3' and 5' binders, e.g., to examine a protein complex having several components, or one 3' binder can be designed to have the potential to react with all 5' binders to examine a large set or possible interactions with proteins, or the protein can be used as a subcellular localization marker for other proteins.

[0160] In multiplex analysis of planar biological samples, multiple binding agents can be designed to bind to multiple sites including proteins, carbohydrates, DNA, RNA, and lipids. Thus, multiplex analysis according to the methods disclosed herein can be used to simultaneously detect multiple proteins, carbohydrates, DNA, RNA, lipids, or any combination of these biomolecules.

[0161] Additional Aspects In designing the different details of the methods disclosed herein (e.g., the sequences of the oligonucleotides used or the specific fluorescent labels), certain aspects may be taken into consideration and are discussed below.

[0162] The sequences of the oligonucleotides bound to the binding agents can be selected so that they are "orthogonal," i.e., so that they do not cross-hybridize with each other. Furthermore, the sequences of the oligonucleotides should be designed to minimize binding to other nucleic acids (e.g., RNA or DNA) endogenous to the sample.

[0163] In some embodiments, the oligonucleotides used in the methods can be independently from 8 nucleotides to 150 nucleotides in length (e.g., ranging from 8 to 100 nucleotides in length), however, in many embodiments, the oligonucleotides are 8 to 50 nucleotides in length, e.g., 10 to 30 nucleotides in length or 11 to 25 nucleotides in length, although oligonucleotides having lengths outside these ranges can often be used.

[0164] In some embodiments, the oligonucleotide has a calculated T in the range of 15° C. to 70° C. (e.g., 20° C. to 60° C. or 35° C. to 50° C.). m may have:

[0165] The oligonucleotides can be attached to the binders using any convenient method (e.g., Gong et al., Bioconjugate Chem. 2016 27:217-225 and Kazane et al. Proc Natl Acad Sci 2012 109:3731-3736). For example, a unique oligonucleotide may be directly attached to the binders utilizing any suitable chemical moiety on the binder (e.g., via a cysteine ​​residue or engineered site). In some embodiments, the oligonucleotides may be directly or indirectly attached to the binders via non-covalent interactions. In some embodiments, the binders may be attached to their respective oligonucleotides by reacting an oligonucleotide-maleimide conjugate with the binder, thereby linking the molecules together.

[0166] In some embodiments, the method may include labeling a sample with multiple binding agents. This step may include contacting the sample (e.g., an FFPE section mounted on a planar support such as a microscope slide) with all the binding agents together under conditions in which the binding agents bind to complementary sites (e.g., protein epitopes or nucleotide sequences) in the sample. Methods for binding antibodies and aptamers to complementary sites in a sample, as well as methods for hybridizing nucleic acid probes to a sample in situ, are well known. In some embodiments, the binding agents may be crosslinked to the sample, thereby preventing the binding agents from dissociating during subsequent steps. This crosslinking step may be performed using an amine-amine crosslinker, although various other chemicals can be used to crosslink the binding agents to the sample, if desired. In some embodiments, the binding agents are not crosslinked to the sample.

[0167] In a particular embodiment, the reading is performed by fluorescence-based imaging (FBI). Fluorophores of interest include xanthene dyes, such as fluorescein and rhodamine dyes, such as fluorescein isothiocyanate (FITC), 6-carboxyfluorescein (commonly known by the abbreviations FAM and F), 6-carboxy-2',4',7',4,7-hexachlorofluorescein (HEX), 6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE or J), N,N,N',N'-tetramethyl-6-carboxyrhodamine (TAMRA or T), 6-carboxy-X-rhodamine (ROX or R), 5-carboxyrhodamine-6G (R6G), and 6-carboxy-X-rhodamine-6G (R6G). 5 Or G 5 ), 6-carboxyrhodamine-6G (R6G 6 Or G 6 ), and rhodamine 110; cyanine dyes, such as Cy3, Cy5 and Cy7 dyes; coumarins, such as umbelliferone; benzimide dyes, such as Hoechst 33258; phenanthridine dyes, such as Texas Red; ethidium dyes; acridine dyes; carbazole dyes; phenoxazine dyes; porphyrin dyes; polymethine dyes, such as BODIPY dyes and quinoline dyes.

[0168] In some embodiments, reading is performed by FBI to detect samples labeled with two, three, or four distinguishable fluorophores, and the method involves repeating the hybridization and detection steps multiple times (at least one or two, up to the number of distinguishable fluorophores), each time using a different bridging oligonucleotide and detection probe directed to a different barcode, and then reading the sample by fluorescence microscopy to generate an image showing the location of the different nucleic acid product molecules on the support.

[0169] In some embodiments, repeated labeling cycles are performed. In particular, up to 4-5 fluorophores are used in each labeling cycle, and several labeling cycles are performed. Each nucleic acid reaction product on the support can be labeled with one label in each cycle. Alternatively, each nucleic acid reaction product can be labeled with several fluorescent labels in the same cycle. Such combinatorial labeling is believed to decode more barcodes per cycle and reduce the time for imaging.

[0170] In further embodiments, each nucleic acid reaction product can be labeled with a specific ratio of fluorescent labels. For example, depending on the combination of barcodes present in the nucleic acid reaction product and the fluorescently labeled probes directed to the different combinations of barcodes, the nucleic acid reaction products can be labeled such that any nucleic acid reaction product can be labeled with 100% of the first fluorescent light but only 50% of the second fluorescent light, while other nucleic acid reaction products can be labeled with 50% of the first fluorescent light and 100% of the second fluorescent light. This increases the number of distinguishable molecules detected in each cycle with a set number of spectrally resolvable dyes.

[0171] In some embodiments, the oligonucleotide and the binding agent are connected via a cleavable linker. In some cases, the cleavable linker can be selectively cleaved using a stimulus (e.g., a chemical, light, or a change in its environment) without breaking any bonds in the oligonucleotide. The cleavable linker facilitates the transfer of the nucleic acid reaction product onto the support by releasing the nucleic acid from the binding agent, thereby releasing the nucleic acid from the target to which the binding agent is specifically bound. Thus, in certain embodiments, the method disclosed herein includes a step of cleaving the linker between the oligonucleotide and the binding agent after step (a) of performing a proximity assay in situ on one or more pairs of binding agents bound to the sample to generate a nucleic acid reaction product, and before step (b) of transferring the nucleic acid reaction product onto the support so as to preserve the spatial relationship of the nucleic acid reaction product in the sample.

[0172] In some embodiments, the cleavable linker may be an enzymatic reaction that allows for cleavage or release of the nucleic acid component from the binding agent. Suitable cleavable bonds that may be used include, but are not limited to, the following: restriction enzyme digestion, site-specific cleavage using uracil DNA glycosylase followed by an endonuclease, or treatment with acidic or basic conditions.

[0173] In some embodiments, the cleavable bond may be a disulfide bond, which may be readily cleaved using a reducing agent (e.g., β-mercaptoethanol, TCEP, etc.). Suitable cleavable bonds that may be used include the following: base-cleavable sites such as esters, particularly succinates (e.g., cleavable by ammonia or trimethylamine), quaternary ammonium salts (e.g., cleavable by diisopropylamine), and urethanes (cleavable by aqueous sodium hydroxide); benzyl alcohol derivatives (cleavable using trifluoroacetic acid), teicoplanin aglycones (cleavable by trifluoroacetic acid followed by base), acetals and thioacetals (also cleavable by trifluoroacetic acid), thioethers (e.g., cleavable by HF or cresol). Examples of suitable cleavable bonds include, but are not limited to, acid cleavable sites such as sulfonyl (cleavable by trifluoromethanesulfonic acid, trifluoroacetic acid, thioanisole, etc.); nucleophilic cleavable sites such as phthalamide (cleavable by substituted hydrazines), ester (cleavable by, for example, aluminum trichloride), and Weinreb amide (cleavable by lithium aluminum hydride); and other types of chemically cleavable sites including phosphorothioates (cleavable by silver or mercury ions) and diisopropyldialkoxysilyl (cleavable by fluoride ions). Other cleavable bonds will be apparent to those of skill in the art or are described in the relevant literature and texts (e.g., Brown (1997) Contemporary Organic Synthesis 4(3); 216-237). In some embodiments, the cleavable bond may be cleaved by an enzyme. In certain embodiments, a photocleavable ("PC") linker (e.g., a UV-cleavable linker) may be used. Photocleavable linkers suitable for use include ortho-nitrobenzyl-based linkers, phenacyl linkers, alkoxybenzoin linkers, chromarene complex linkers, NpSSMpact linkers, and pivaloyl glycol linkers, as described in Guillier et al. (Chem Rev. 2000 Jun14;100(6):2091-158).Exemplary linking groups that can be used in the present method are described above in Guillier et al. and Olejnik et al. (Methods in Enzymology 1998 291:135-154), and further described in USPN 6,027,890; Olejnik et al. (Proc. Natl. Acad Sci, 92:7590-94); Ogata et al. (Anal. Chem. 2002 74:4702-4708); Bai et al. (Nucl. Acids Res. 2004 32:535-541); Zhao et al. (Anal. Chem. 2002 74:4259-4268); and Sanford et al. (Chem Mater. 1998 10:1510-20), and are disclosed in Ambergen (Boston, MA; NHS-PC-LC-Biotin), Link Technologies (Bellshill, Scotland), Fisher Scientific (Pittsburgh, PA), and Calbiochem-Novabiochem Corp. (La Jolla, CA).

[0174] In some embodiments, the cleavable linker comprises a bond (e.g., a disulfide bond) that is cleavable by a reducing agent. In these embodiments, the label can be removed using a reducing agent, such as tris(2-carboxyethyl)phosphine (TCEP).

[0175] In embodiments where the sample is read by fluorescence, each reading step may generate an image of the nucleic acid product molecules distributed on the support. In some embodiments, the method may further include analyzing, comparing, or overlaying at least two images. In some embodiments, the method may further include overlaying all images to generate an image showing the distribution pattern of the different nucleic acid product molecules on the support. The image analysis module used may convert the signal from each fluorophore to generate multiple false color images. The image analysis module may overlay multiple false color images (e.g., superimpose a false color on each pixel) to obtain a multiplexed false color image. For example, multiple images (e.g., unweighted or weighted) may be converted to a single false color to represent a biological feature of interest characterized by the binding of a specific binding agent. Based on manual input from the user, the false color may be assigned to a specific binding agent or combination of binding agents. In certain aspects, the image may include false colors related only to the intensity of the label associated with the feature of interest, such as within the nuclear compartment. The image analysis module may further be configured to adjust (e.g., normalize) the intensity and / or contrast of the signal intensity or false color, perform a deconvolution operation (such as blurring or sharpening the intensity or false color), or perform any other suitable operation to enhance the quality of the image. The image analysis module may perform any of the above operations to align pixels from consecutive images and / or blur or smooth the intensity or false color of pixels from consecutive images.

[0176] In some cases, the nucleic acid reaction products are transferred to a three-dimensional (3-D) gel matrix. The gel can be selected to immobilize only the tissue-bound nucleic acid reaction products, but not other biomolecules from the biological sample. Examples of such gel matrices include polyacrylamide gels and silica gel. Proteins, RNA, DNA, and unligated oligonucleotides, as well as other biomolecules, can be digested, thereby leaving only the nucleic acid reaction products in the gel. The nucleic acid reaction products can be protected from enzymatic digestion using exonuclease-protecting modifications. Thus, upon digestion of other biomolecules, only the nucleic acid reaction products remain in the gel. The nucleic acid reaction products can also be equipped with the functionality to crosslink them to the 3D gel matrix, thereby spatially immobilizing them in the gel for subsequent analysis when other molecules are removed from the gel.

[0177] Alternative in situ embodiments In some embodiments, the proximity assay reaction products may persist in tissue at the site where they are made. In these embodiments, the proximity assay reaction products may be detected in situ using programmable hybridization.

[0178] In situ proximity assays have traditionally involved RCA (rolling circle amplification) followed by in situ detection of the RCA products, for example, by hybridization to a labeled probe that hybridizes to the RCA products. However, as mentioned above, RCA products are relatively large molecules and require physical space to be efficiently generated. Often, RCA products are generated inconsistently with respect to both their density and length. As a result, in any one experiment, some RCA products may be densely packed, while others may be sparsely packed. Similarly, some RCA products may occupy large physical spaces, while others may occupy small spaces. These issues often confound the results.

[0179] In the in situ embodiment of the method of the invention, the "spots" observed after the proximity assay reaction products are labeled should be bright, of consistent size, and have consistent intensity. Furthermore, the spots are much smaller than those obtained by RCA-based methods, so many more spots can be observed. Furthermore, the method allows for multiplexing, which is not possible using RCA-based methods. Some of the same advantages may be applicable to embodiments in which the proximity assay reaction products are transferred to a support, as described above.

[0180] Filter embodiment In any embodiment, the planar sample may be generated by passing a suspension of cells through a filter, with the cells being retained on the filter. A method for analyzing a suspension of cells is provided. In some embodiments, the method may include (a) filtering the suspension of cells through a porous capillary membrane, thereby distributing the cells on the membrane; (b) placing the membrane on the support with the cell side of the membrane facing the planar support; (c) transferring nucleic acids from the cells into or onto the support, so as to preserve the spatial relationship of the nucleic acids in the cells; (d) removing the porous capillary membrane and the cells from the support; and (e) spatially analyzing the nucleic acids transferred to the support.

[0181] As mentioned above, the present specification provides, among others, a method for analyzing a suspension of cells, which may include: (a) filtering the suspension of cells through a porous capillary membrane, thereby distributing the cells on the membrane; (b) placing the membrane on a support, with the cell side of the membrane facing the planar support; (c) transferring nucleic acid from the cells into or onto the support, so as to preserve the spatial relationship of the nucleic acid in the cells; (d) removing the porous capillary membrane and the cells from the support; and (e) spatially analyzing the nucleic acid transferred to the support.Some principles of this method are shown in Figure 14.

[0182] In some embodiments, the method may further comprise performing a proximity assay in situ on one or more pairs of binder-oligonucleotide conjugates bound to the cells prior to step (c), e.g., between steps (a) and (c), to generate proximity assay reaction products in or on the cells. Some principles of this embodiment are shown diagrammatically in FIG. 14. In these embodiments, the nucleic acids transferred in step (c) and analyzed in step (e) comprise proximity assay reaction products. In these embodiments, the analyzing step may comprise (i) labeling the proximity assay reaction products transferred in or on the support, and (ii) imaging the support to generate an image of the sites where the proximity assay reaction products are bound in or on the support. The proximity assay may comprise any combination of ligation, primer extension, and gap-fill / ligation reactions involving oligonucleotides of the binder-oligonucleotide conjugates. Examples of such assays are described elsewhere in this disclosure.

[0183] In some cases, the RNA can be transferred from the cell onto a substrate. In some embodiments, the support is a polyA + The planar support may be coated with an oligo(T) that hybridizes to the RNA. In other embodiments, the planar support of (b) may include an array of spatially barcoded capture oligonucleotides, and step (c) includes hybridizing the transferred nucleic acid to the spatially barcoded capture oligonucleotides, and step (e) includes extending the capture oligonucleotides using the transferred nucleic acid as a template and sequencing the copies of the primer extension template to generate sequence reads. See, for example, Nerurkar et al. (Cancers (Basel). 2020 12:2572) for a description of some aspects of this method. In these embodiments, the method may include mapping the sequence reads to sites on the support using spatial barcodes in the sequence reads.

[0184] The transfer step (c) can be performed by electrophoresis or diffusion. In any embodiment, the porous capillary membrane can be a porous anodic aluminum oxide (AAO) membrane, although other filters are known and can be used.

[0185] In any embodiment, the method may include (i) disposing a suspension of cells on a porous capillary membrane and (ii) applying a force to move a liquid component of the suspension through the membrane. In these embodiments, the force may be, for example, an active force selected from centrifugal force, negative pressure, and positive pressure, or a passive force selected from capillary action and evaporation.

[0186] As described above, the filter may be coated with a method that allows cells to adhere to the filter, e.g., via electrostatic interactions. In some embodiments, the method may include washing the porous capillary membrane as needed, e.g., between steps (d) and (e), to remove residual reactants, etc.

[0187] In any embodiment, the inner diameter of the pores in the membrane is in the range of 2 nm to 500 nm, the average distance between the centers of adjacent pores in the membrane is in the range of 50 nm to 1000 nm, and the average distance between the edges of adjacent pores in the membrane is in the range of 10 nm to 500 nm. These distances can be adjusted as needed.

[0188] In any embodiment, the suspension of cells may include blood cells, immune cells (e.g., immune cells isolated from blood), single cells separated from one another by trypsinization, or cells cultured as a suspension.

[0189] Conventional methods for depositing a suspension of cells onto a surface often involve depositing the cells onto the surface and waiting for the cells to spread or settle to the surface. These methods take a significant amount of time and not all cells reach the surface. In addition, because cells settle in a pattern determined by a Poisson distribution, conventional methods can result in a significant number of overlaps and clumps, which can confound subsequent analysis. The use of a filter ensures that all cells reach the surface very quickly. Furthermore, because the cells move in the direction of the liquid flow, the cells should be spread more evenly (e.g., adjacent to each other rather than on top of each other) than in other methods.

[0190] This method finds use in transferring RNA from cells to a support (e.g., an oligod(T)-coated surface or a spatially barcoded array of oligonucleotides) and transferring proximity assay products to a support (e.g., a glass slide) so that the products can be labeled and then analyzed on the support. In some embodiments, the method may include performing a proximity assay in situ on one or more pairs of binder-oligonucleotide conjugates bound to the cells to generate proximity assay reaction products in or on the cells, and transferring the proximity assay reaction products to the support. As described in more detail below, the proximity assay reaction products transferred to the support may be generated in a variety of different ways, for example, by performing ligation, primer extension, gap-fill / ligation, or any hybridization thereof, between the oligonucleotides of the binder-oligonucleotide conjugates such that the sequence of one of the oligonucleotides is covalently linked to another oligonucleotide or copy thereof, and then transferring the first product to the support. Alternatively, the first product or unligated oligonucleotide may serve as a splint for ligating other oligonucleotides together to generate a second product. In these embodiments, the second product may be transferred to the support.

[0191] In some cases, multiple samples may be "hash tagged" prior to mixing and analysis (see, e.g., Stoeckius et al. Genome Biology 2018 19:224). In these embodiments, cells may be mixed with sample barcoding affinity reagents (e.g., barcoded antibodies), allowing samples to be multiplexed.

[0192] As the cells pass through the filter, they become more separated from other cells on the solid phase, as opposed to methods that may rely on random distribution. This allows many of the downstream processes to function more efficiently and collect more meaningful data. As will be apparent from the following description, the cells may be immobilized on the filter, or the cells may be fixed and permeabilized while on the filter. The structure of the filter can vary widely. However, in many cases, the filter may have elements (physical structure, e.g., mediated by pores, or another surface chemistry) that allow the cells to self-assemble into regular patterns, thereby maximizing the use of surface area.

[0193] In some embodiments, a capture agent conjugated to a barcoded oligonucleotide (e.g., a binder-oligonucleotide conjugate, where the oligonucleotide has a barcode that identifies the antigen to which the antibody is conjugated) can be introduced into or onto a cell. The probe binds to a specific molecule, e.g., DNA, RNA, or protein. After removing unreacted probe (e.g., using washing or enzymatic digestion, etc.), the binding event can then be converted into a reporter molecule that can be transferred (or "blotted") to another surface. In these embodiments, the reporter is transferred from the cell to the surface of the support (e.g., a slide) in a manner that preserves the relative spatial location of the molecules. The reporter becomes attached to the support and can be detected on the support using optical single molecule resolution. Multiplex analysis can be performed using cyclic decoding if the samples are hash-tagged, and the sample from which the cells originate can be determined by analysis of the sample barcodes added before pooling.

[0194] The method allows cells to be analyzed in a highly multiplexed manner. The filtering step provides a high yield in the number of available cells that are actually analyzed. Using a single molecule combinatorial readout on a surface can potentially avoid the use of next generation sequencing instruments for data generation, thereby reducing the cost of analysis and providing high spatial resolution. As mentioned above, hash tagging allows many samples to be analyzed in parallel and allows the identity of the samples to be decoded during analysis.

[0195] One advantage of this method is that cells on the surface of a filter are difficult to interrogate optically, and furthermore, immobilizing cells on a non-porous surface can be very slow and inefficient.

[0196] As described in more detail below, the method may include performing a proximity assay in situ on one or more pairs of binder-oligonucleotide conjugates bound to cells to generate a proximity assay reaction product in or on the cells, and then transferring the proximity assay reaction product to a support. In these embodiments, each binder-oligonucleotide conjugate includes i. a binder that binds to a site or sequence in the sample, and ii. a first oligonucleotide. In some cases, the proximity assay may include binding a pair of reporter oligonucleotides together in situ to generate a reporter probe, where binding of the reporter oligonucleotides is templated by either i. the first oligonucleotides that are in proximity to each other, or ii. their ligation product. The reporter probes are then transferred to the support, where they are detected.

[0197] In some embodiments, the proximity assay can be a ligation-based assay for analyzing DNA or RNA, or a ligation-based proximity assay for analyzing proteins, protein-protein interactions, or protein modifications. In some cases, the method can create a biotinylated reporter molecule that is protected from exonuclease degradation by ligation of two molecules that are protected at the end that does not participate in the ligation reaction.

[0198] In some embodiments, RNA molecules may be transferred and captured onto a receiving surface, for example, using an oligo(T) capture oligonucleotide. The captured RNA molecules may then be covalently immobilized to a substrate and interrogated on the substrate using a probe-based approach (e.g., using single molecule FISH or padlock probe / RCA-based approaches).

[0199] In some embodiments, antibody-oligonucleotide conjugates can be used to examine the presence of proteins in or on cells. In these embodiments, the oligonucleotides can be released after the antibody is bound to the cells and washed. In these embodiments, the released oligonucleotides can be designed to have, for example, biotin to facilitate capture on a receiving surface. Hybridization probes for RNA and DNA analysis can be used that are wholly or partially released during blotting and captured on a receiving surface using, for example, a capture surface coated with biotin moieties and streptavidin.

[0200] The filter can be an anodic aluminum oxide (AAO) filter, or any filter that allows for the capture of cells and subsequent blotting of biomolecules from the cells. Such filters can have micro- or nanostructured permeable surfaces with structures that use flow to direct cells to different locations on the filter such that cells sit above the pores and potentially block the pores, thereby inhibiting other cells from locating in the same compartment. In some embodiments, surfaces modified to attract or repel cells to specific locations can be used. In some cases, once the cells are immobilized, overflow / excess cells can be washed off the surface.

[0201] This method is particularly used in the analysis of peripheral blood cells and immune cells in blood. Blood cells can be enriched for specific subtypes to target the analysis to a specific cell type of interest. Blood cells can be examined, for example, for surface receptors to elucidate immune responses, receptor affinity to secreted factors or antigens, analysis of pathway activation status using nucleic acid-labeled antibodies, etc. This method can also be used to analyze CRISPR screening using expression barcodes associated with CRISPR inserts in combination with analyzing effects on gene expression, protein expression, and protein interactions and modifications to analyze cell cultures in a multiplexed manner. This method can also be used to analyze isolated cells obtained from tissues in a multiplexed manner.

[0202] In some cases, cells may be advantageously fixed, for example using PFA, prior to filtering and permeabilization to allow analysis of intracellular RNA and / or proteins.

[0203] The proximity assay method may include binding cells with a plurality of binder-oligonucleotide conjugates and performing a proximity assay in situ on the bound conjugates. Binding can be performed before or after the cells are distributed on the filter. The binder portion of the conjugate may be an antibody. However, in other embodiments, the binder may be an aptamer or an oligonucleotide probe. The proximity assay may be performed using a variety of different methods, such as a proximity ligation assay (where the ends of the oligonucleotides in the conjugates that bind to the proximity site are ligated to each other, resulting in a first product), or a proximity extension assay (where one or both oligonucleotides are extended using the other as a template, resulting in a first product). In either case, the first products may be released from the binders to which they are tethered and then transferred to the support as proximity assay reaction products in step (c). In these embodiments, the proximity assay reaction products transferred to the support in step (c) are the first products. In other cases, the first product can be used as a splint to ligate a pair of tailed detection oligonucleotides together to create a second product. In these embodiments, the proximity assay reaction products transferred to the support in step (c) are the second products. The proximity assay reaction products can be transferred to the support in a way that preserves their spatial relationship in the xy plane, and then the filter (and the cells attached thereto) are removed from the support. In this method, the transferred nucleic acids are tethered to the support and can then be detected on the support, for example, by hybridizing (directly or indirectly) labeled probes to the tethered proximity assay reaction products while placing them on the support and analyzing the label pattern by microscopy. The support can be a planar substrate, such as a slide (which may be coated), or a three-dimensional substrate, such as a gel. When the substrate is a planar substrate, the proximity assay reaction products are on the substrate. When the substrate is a three-dimensional substrate, the proximity assay reaction products are in the substrate.

[0204] The method can be carried out with any type of capture support that can function as a filter for cells. Such a filter should allow rapid fluid flow-through of liquid and have a pore size sufficient to capture cells. Suitable capture supports can be made from porous organic or inorganic materials, including solids such as porous metals, ceramics, homogeneous films (e.g., polymers) and heterogeneous solids (polymer mixtures, mixed glasses). Porous ceramic membranes can be made from inorganic materials (e.g., alumina, titania, zirconia oxide, recrystallized silicon carbide). See, for example, PamChip sold by Pamgene (The Netherlands), Wu et al., Nucleic Acids Res. 2004 32:e123 and Anthony et al. Biotechniques. (2003) 34:1082-6, 1088-9. Exemplary porous polymeric membranes can be made from cellulose acetate, nitrocellulose, cellulose esters (CA, CN, and CE), polysulfone (PS), polyether sulfone (PES), polyacrylonitrile (PAN), polyamide, polyimide, polyethylene and polypropylene (PE and PP), polytetrafluoroethylene (PTFE), polyvinylidene fluoride (PVDF), and polyvinylchloride (PVC).

[0205] In any embodiment, the pores of the capillary membrane should be sized to prevent cells from passing through the pores. For example, in embodiments, the pore size of the capillary membrane may be 50% or less of the median cell size, and in some embodiments, it may be 10% or less of the median cell size. Thus, when using a porous capillary membrane to filter a sample, cells should remain on the membrane and not enter or pass completely through the pores.

[0206] In certain embodiments, the porous capillary membrane may include a coating that binds to cells and / or a patterned surface (eg, an array of hydrophilic or hydrophobic regions) that aids in separating cells.

[0207] The inner diameter of the pores in the membrane, the distance between the centers of adjacent pores in the membrane, and the distance between the edges of adjacent pores in the membrane can be controlled by deposition voltage, type of acid, and other parameters (see generally, Poinern, supra). In some embodiments, the inner diameter of the pores in the membrane can be in the range of 5 nm to 500 nm, e.g., 4 nm to 250 nm, 4 nm to 50 nm, 50 nm to 100 nm, 100 nm to 200 nm, or 200 nm to 500 nm. Independently, the average distance between the centers of adjacent pores in the membrane can be in the range of 50 nm to 1000 nm, e.g., 50 nm to 420 nm, 50 nm to 100 nm, 100 nm to 250 nm, 250 nm to 500 nm, or 500 nm to 1000 nm. The average distance between the edges of adjacent pores in the membrane may be in the range of 10 nm to 500 nm, 10 nm to 50 nm, 50 nm to 200 nm, or 200 nm to 500 nm. It can be understood that the values ​​of diameter and average distance between pores provided herein are exemplary, and such values ​​may vary based on the embodiment. The membrane used may be of any suitable thickness, for example, in the range of 20 μm to 500 μm or 50 μm to 200 μm, as desired, and may include one or more support structures (e.g., support rings) to maintain the integrity of the membrane during use, as described above.

[0208] As mentioned above, the suspension of cells may include blood cells, immune cells, single cells separated from each other by trypsinization, or cells cultured as a suspension, etc. In these embodiments, the term "blood sample" or its grammatical equivalents refers to a sample of whole blood or subpopulations of cells in whole blood. Subpopulations of cells in whole blood include platelets, red blood cells (erythrocytes), platelets, and white blood cells (i.e., peripheral blood white blood cells, which are composed of neutrophils, lymphocytes, eosinophils, basophils, and monocytes). These five types of whole blood cells can be further divided into two groups: granulocytes (also known as polymorphonuclear leukocytes, which include neutrophils, eosinophils, and basophils), and mononuclear white blood cells (which include monocytes and lymphocytes). Lymphocytes can be further divided into T cells, B cells, and NK cells. Peripheral blood cells are found in the circulating pool of blood and are not sequestered within the lymphatic system, spleen, liver, or bone marrow. When blood is first contacted with the agent and then a sample of the blood is used in the assay, a part or all of the contacted blood can be used in the assay. Blood is only one of many biological samples that can be used in this method. In other embodiments, intact cells from other tissues (e.g., other soft tissues such as liver or spleen) or cells grown in tissue culture can be used. Methods for processing such tissues to provide a cell suspension suitable for flow cytometry are known. Once generated, the cell suspension can be used in a similar manner to the method described below. Cell suspensions can be made from soft tissues such as brain, adrenal gland, skin, lung, spleen, kidney, liver, spleen, lymph node, bone marrow, bladder, stomach, small intestine, large intestine or muscle, as well as monolayers of cells.

[0209] In some embodiments, the cells may be contacted with the test agent ex vivo (i.e., using blood drawn from a subject) or in vivo (e.g., by administering the test agent to a mammal), and the results from the assay may be compared to results obtained from a reference sample of cells (e.g., blood cells that have not been contacted with the test agent or a different amount of the test agent).

[0210] The suspension applied to the filter must contain at least 1,000 particles and at least 10 4 Pieces, at least 10 5 Pieces, at least 10 6 The cell may contain cells.

[0211] In some cases, the methods disclosed herein include removing the filter (and cells) from the support, leaving the transferred nucleic acid on or in the support.

[0212] The filter can be removed from the support in any suitable manner. For example, the substrate, such as a glass slide, on which the planar biological sample is placed can be simply removed from the support. Since the nucleic acid reaction products are bound to the support either covalently or non-covalently, the nucleic acid reaction products remain attached to the support, but the filter is removed from the support.

[0213] Any remaining residues of the biological sample can be removed by enzymatic action. For example, the support can be treated with an enzyme that degrades biomolecules other than polynucleotides, thereby removing only biomolecules other than nucleic acids. Furthermore, if the nucleic acid reaction products include DNA, the support can be treated with an RNase to remove contaminating RNA. The support can be treated, for example, with a cocktail of exonucleases.

[0214] kit The present disclosure also provides a kit comprising the reagents for carrying out the method as described above. These various components of the kit may be in separate containers or may be mixed in the same container.

[0215] The various components of the kit may be present in separate containers or, if desired, certain compatible components may be precombined in a single container.

[0216] In addition to the above components, the subject kits can further include instructions for using the kit components to practice the subject methods.

[0217] usefulness The methods and compositions described herein find general use in a wide variety of applications for the analysis of planar biological samples (e.g., in the analysis of tissue sections, sheets of cells, or spun down cells). This method can be used to analyze any tissue, including tissues that have been cleared, such as by lipid removal. Samples may be prepared using expansion microscopy (see, e.g., Chozinski et al., Nature Methods 2016 13:485-488), which involves creating polymeric replicas of biological systems made by selective copolymerization of organic polymers with cellular components. This method can be used to analyze, for example, cell diffusions, exosomes, extracellular structures, biomolecules deposited on solid supports or in gels (Elisa, Western blots, dot blots), whole organisms, individual organs, tissues, cells, extracellular components, organelles, cellular components, chromatin and epigenetic markers, biomolecules and biomolecular complexes. The binding agents can bind to any type of molecule, including proteins, lipids, polysaccharides, proteoglycans, metabolites, nucleic acids, or artificial small molecules. This method may have many biomedical applications, such as in screening and drug discovery. Additionally, this method has a variety of clinical applications, including, but not limited to, diagnosis, prognosis, disease stratification, personalized medicine, clinical trials, and drug contingency testing.

[0218] In the field of spatial analysis techniques, the present disclosure aims to provide highly multiplexed readouts of protein-protein interactions and protein modifications in situ. The present disclosure also enables single molecule analysis of proteins, protein post-translational modifications, and protein interactions.

[0219] The methods disclosed herein can also be used to analyze RNA, or RNA interactions between RNA and other molecules (eg, proteins) in a single assay format.

[0220] In some cases, the method disclosed herein can be used to analyze target RNA.For example, as described above, the RNA target from planar biological sample can be directly copied into reporter polynucleotide using reporter probe.In particular, the proximity assay is not performed to generate nucleic acid reaction products, but the RNA target is used as a template to generate reporter polynucleotide.Such a step can be performed before contacting the sample with the binder, or simultaneously with the introduction of the detection oligonucleotide that ligates to the first product created by binding the nucleic acid of the binder, since, for example, the antigen retrieval step required for protein analysis can damage RNA, but not DNA.

[0221] Additionally, the methods disclosed herein can be used to analyze interactions of RNA with other biomolecules (e.g., RNA, proteins, DNA, carbohydrates, lipids, etc.). In certain such embodiments, a proximity assay can be performed using one binding agent that targets RNA and another that targets a protein, carbohydrate, or lipid. A proximity assay can also be performed using one binding agent that targets RNA and another that targets a different RNA. Such embodiments can be used to analyze interactions of a target RNA to any other biomolecule for which a specific binding agent is available.

[0222] In some cases, the method disclosed herein can be used to identify target sites that are located close to each other.For example, a first binding agent-oligonucleotide conjugate binds to a first site, and a second binding agent-oligonucleotide conjugate binds to a second site.When the first site and the second site are close to each other, the oligonucleotides are close to each other.Therefore, the generation of nucleic acid from the oligonucleotide that is conjugated to the first and second binding agent-oligonucleotide conjugates indicates that the oligonucleotide is conjugated to a binding agent that is bound to a site that is close to each other.

[0223] Thus, in certain cases, the methods disclosed herein can be used to determine where a particular protein is located in a planar biological sample, in these embodiments, the binding agents bind to different sites on the same protein.

[0224] In some cases, the methods disclosed herein can also be used to identify where protein-protein interactions occur, in these embodiments, the binding agents bind to different proteins.

[0225] This is advantageous because the relative proximity of targets depends on absolute concentration, and the amount of signal generated from each interaction depends on further efficiency factors such as binding affinity and chemical and enzymatic efficiency that relate relative signals to each other within a multiplex experiment.For example, using reference proteins, RNA or DNA targets, or relating the signal from a single individual protein to the signal from protein interactions.Signals can be analyzed cell by cell within a cell population, for example, with cell type determined by the presence or area of ​​cell markers.

[0226] Also, in some cases, the methods disclosed herein can be used to determine post-translational modifications of biomolecules such as proteins. In certain such embodiments, one binding agent binds to a post-translational modification or to an epitope that covers both the post-translational modification and the target protein, and the other binding agent binds to a different site in the same protein. The generation of nucleic acids from oligonucleotides conjugated to the first and second binding agent-oligonucleotide conjugates indicates that the protein has a post-translationally modified site. By using binding agents specific for common post-translational modifications, the presence of such modifications across a large number of proteins can be examined. Signals can be advantageously analyzed in a relative manner to normalize the effect of the overall presence of the modification, the effect of protein concentration, and assay efficiency.

[0227] In certain embodiments, the sample may be a section of a tissue biopsy obtained from a patient. Biopsies of interest include both tumor and non-tumor biopsies of the skin (e.g., melanoma, carcinoma), soft tissue, bone, breast, colon, liver, kidney, adrenal gland, gastrointestinal tract, pancreas, gallbladder, salivary gland, cervix, ovary, uterus, testes, prostate, lung, thymus, thyroid, parathyroid, pituitary gland (e.g., adenoma), brain, spinal cord, eye, nerve, and skeletal muscle.

[0228] In certain embodiments, the binding agent specifically binds to a biomarker, including a cancer biomarker that may be proteinaceous. Exemplary cancer biomarkers include, but are not limited to, carcinoembryonic antigen (for identifying adenocarcinomas), cytokeratin (for identifying carcinomas, but may also be expressed by some sarcomas), CD15 and CD30 (for Hodgkin's disease), alpha-fetoprotein (for yolk sac tumors and hepatocellular carcinomas), CD117 (for gastrointestinal stromal tumors), CD10 (for renal cell carcinomas and acute lymphoblastic leukemia), prostate-specific antigen (for prostate cancer), estrogen and progesterone (for identifying tumors), CD20 (for identifying B-cell lymphomas), and CD3 (for identifying T-cell lymphomas).

[0229] The above method can be used to analyze cells from a subject, for example, to determine whether the cells are normal or to determine whether the cells are responding to a treatment. In one embodiment, the method can be used to determine the degree of dysplasia of cancer cells. In these embodiments, the cells can be samples from multicellular organisms. The biological sample can be isolated from an individual, for example, from soft tissue. In certain cases, the method can be used to distinguish different types of cancer cells in FFPE samples.

[0230] The above method finds particular utility when testing samples using multiple antibodies or antibody pairs, each antibody or antibody pair recognizing a different marker. Examples of cancers and biomarkers that can be used to identify those cancers are listed below. In these embodiments, it is not necessary to test all of the markers listed below to make a diagnosis.

[0231] [Table 1]

[0232] In some embodiments, the method may include obtaining data (images) as described above (whose electronic form may be transferred from a remote location), which may be analyzed by a physician or other medical professional to determine whether a patient has abnormal cells (e.g., cancerous cells) or what type of abnormal cells are present. The images may be used as a diagnostic to determine whether a subject has a disease or condition, e.g., cancer. In certain embodiments, the method may be used, for example, to determine the stage of cancer, identify metastatic cells, or monitor a patient's response to treatment.

[0233] Cell markers can also be investigated, including markers for T cells, B cells, and neutrophils (e.g., CD3, CD20, CD15, etc.). The compositions and methods described herein can be used to diagnose patients with disease. In some cases, the presence or absence of a biomarker in a patient's sample can indicate that the patient has a particular disease (e.g., cancer). In some cases, a patient can be diagnosed as having a disease by comparing a sample from a patient to a sample from a healthy control. In this example, the level of the biomarker relative to the control can be measured. A difference in the level of the biomarker in the patient's sample relative to the control can be indicative of the disease. In some cases, more than one biomarker is analyzed to diagnose a patient with a disease. The compositions and methods of the present disclosure are particularly suitable for identifying the presence or absence of multiple biomarkers in a sample, or for measuring their expression levels.

[0234] In some cases, the compositions and methods herein can be used to determine a treatment plan for a patient. The presence or absence of a biomarker may indicate whether a patient is responsive or refractory to a particular therapy. For example, the presence or absence of one or more biomarkers may indicate that a disease is refractory to a particular therapy, and an alternative therapy may be implemented. In some cases, a patient is currently undergoing treatment, and the presence or absence of one or more biomarkers may indicate that the treatment is no longer effective.

[0235] In some cases, the methods may be used in a variety of diagnostic, drug discovery, and research applications, including, but not limited to, diagnosing or monitoring a disease or condition (where the image identifies markers for a disease or condition), drug target discovery (where markers in the image may be targeted for drug therapy), drug screening (where the effects of drugs are monitored by markers shown in the image), determining drug susceptibility (where drug susceptibility is related to the marker), and basic research (where it is desirable to measure differences between cells in a sample).

[0236] In certain embodiments, the above method can be used to compare two different samples. The different samples can be composed of a "test" sample, i.e., a sample of interest, and a "control" sample that can be compared to the test sample. In many embodiments, the different samples are pairs of cell types or fractions thereof, where one cell type is a cell type of interest, e.g., an abnormal cell, and the other is a control, e.g., a normal cell. When two fractions of cells are compared, the fractions are usually the same fraction from each of the two cells. However, in certain embodiments, two fractions of the same cell may be compared. Exemplary cell type pairs include, for example, cells isolated from a tissue biopsy (e.g., tissue with a disease such as colon cancer, breast cancer, prostate cancer, lung cancer, skin cancer, or tissue infected with a pathogen) and normal cells from the same tissue, usually the same patient; cells grown in tissue culture that are immortal (e.g., cells with a proliferative mutation or immortalizing transgene), infected with a pathogen, or treated (e.g., with environmental or chemical agents such as peptides, hormones, altered temperature, growth conditions, physical stress, cell transformation, etc.) and normal cells (e.g., cells that are not immortal, uninfected or untreated but are otherwise identical to the experimental cells); cells isolated from a mammal with cancer, a disease, an aged mammal, or a mammal exposed to a condition, and cells from the same species, preferably the same family of mammals, that are healthy or young; and differentiated and undifferentiated cells from the same mammal (e.g., one cell is a precursor of the other cell in the mammal, for example). In one embodiment, cells of different types, e.g., neuronal and non-neuronal cells, or cells in different states (e.g., before and after stimulation of the cells) may be used. In another embodiment of the invention, the experimental material comprises cells susceptible to infection by a pathogen, such as a virus, e.g., human immunodeficiency virus (HIV), and the control material comprises cells resistant to infection by the pathogen, hi another embodiment, the pair of samples is represented by undifferentiated cells, e.g., stem cells, and differentiated cells.

[0237] The images produced by the method may be viewed side by side, or in some embodiments the images may be overlaid or combined. In some cases, the images may be in color, and the colors used in the images may correspond to the labels used.

[0238] Cells derived from any organism can be used in the present methods, including bacteria, yeast, plants, and animals such as fish, birds, reptiles, amphibians, and mammals, hi certain embodiments, mammalian cells, i.e., cells derived from mice, rabbits, primates, or humans, or cultured derivatives thereof, may be used.

[0239] Embodiment Embodiment F1. A method for analyzing a sample, comprising: A method comprising: (a) contacting an oligonucleotide or a conjugate comprising the oligonucleotide with a planar biological sample under conditions in which the oligonucleotide or conjugate specifically binds to a site in or on the planar biological sample; (b) performing one or more steps in situ to release and / or extend the oligonucleotide or a complementary sequence of the oligonucleotide to generate a reporter probe; (c) transferring all or a portion of the reporter probe from the sample to a planar support that does not contain an array of oligonucleotides, so as to preserve the spatial relationship of the reporter probe in the sample; and (d) detecting the reporter probe on the support.

[0240] Embodiment F2. Step (a) comprises hybridizing an oligonucleotide to a sample under conditions in which the oligonucleotide hybridizes to endogenous RNA or DNA in the sample; The method of embodiment F1, wherein step (b) comprises joining together via ligation or gap-fill / ligation any oligonucleotides that hybridize to adjacent sites in the RNA or DNA.

[0241] Embodiment F3. The sample comprises ligation products from a proximity ligation assay, Step (a) comprises hybridizing an oligonucleotide to the sample under conditions in which the oligonucleotide hybridizes to the ligation product; The method of embodiment F1, wherein step (b) comprises joining together any oligonucleotides that hybridize to adjacent sites in the ligation product via ligation or a gap-fill / ligation reaction.

[0242] Embodiment F4. The method of embodiment F1 or F2, wherein the oligonucleotide is exonuclease sensitive but the reporter probe is exonuclease resistant.

[0243] Embodiment F5. The method of embodiment F4, wherein the method further comprises treating the sample with an exonuclease between steps (b) and (c).

[0244] Embodiment F6. Step (a) comprises contacting a tissue sample with an antibody-oligonucleotide conjugate under conditions in which the antibody binds to sites in or on the sample; The method of embodiment F1, wherein step (b) comprises cleaving the oligonucleotide or an extension product of the oligonucleotide from the conjugated antibody to produce the reporter probe.

[0245] Embodiment F7 The method of embodiment F1, wherein the reporter probe is generated via a ligation or gap-fill reaction.

[0246] Embodiment F8. The method of embodiment F1, wherein the reporter probe is generated via a primer extension reaction.

[0247] Embodiment F9. The method of any of embodiments F1-F8, wherein step (d) is performed by microscopy.

[0248] Embodiment F10. The method of embodiment F9, wherein step (d) comprises hybridizing a labeled probe to a reporter probe and then analyzing the binding pattern of the probe by microscopy.

[0249] Embodiment F11. The method of embodiment F10, wherein the set of probes are hybridized and washed in repeated cycles to decode individual reporter molecules, which are decoded using at least two or more cycles.

[0250] Embodiment F12. The method of any of embodiments F1-F11, wherein the sample is a tissue section.

[0251] Embodiment F13. The method of any of embodiments F1-F12, wherein the sample is a mammalian cell.

[0252] Embodiment F14. The method of any of embodiments F1-F13, wherein the releasing is effected by contacting the biological sample with the support after step (a) such that the biological sample faces the support, and then heating the sample.

[0253] Embodiment A1. A method for analyzing a planar biological sample, comprising: (a) performing an in situ proximity assay on one or more pairs of binding agent-oligonucleotide conjugates bound to a sample to generate a proximity assay reaction product; (b) transferring the nucleic acid reaction products into or onto the support in a manner that preserves the spatial relationship of the proximity assay reaction products in the sample; (c) detecting the proximity assay reaction product in or on the support.

[0254] Embodiment A2. The method of embodiment A1, wherein the proximity assay comprises any combination of ligation, primer extension, and gap-fill / ligation reactions involving oligonucleotides of the binder-oligonucleotide conjugate.

[0255] Embodiment A3. The method of embodiment A1, wherein the support is a planar support.

[0256] Embodiment A4. The method of embodiment A1, wherein the support is a matrix.

[0257] Embodiment A5. The method of embodiment A1, wherein the support is a gel.

[0258] Embodiment A6. Step (c) comprises: (b)(i) labeling the proximity assay reaction products in or on the support; The method of any of embodiments A1-A5, comprising (ii) imaging the support to generate an image of sites where the proximity assay reaction products are bound in or on the support.

[0259] Embodiment A7. The method of any of embodiments A1 to A6, wherein the moving in step (b) is carried out by disposing the sample on a support and moving the proximity assay reaction products onto the surface of the support by electrophoresis or diffusion.

[0260] Embodiment A8. The method of any of embodiments A1-A7, wherein step (c) comprises hybridizing one or more labeled oligonucleotides directly or indirectly to the nucleic acid reaction product.

[0261] Embodiment A9. The method of any of embodiments A1 to A8, wherein in step (c) the proximity assay reaction products are detected by hybridization to a defined nucleic acid structure composed of a predetermined number of oligonucleotides and a predetermined number of labeled oligonucleotides.

[0262] Embodiment A10. The method of embodiment A9, wherein the structure is nucleated by at least two hybridization events to the proximity assay reaction products.

[0263] Embodiment A11. The method of embodiment A10, wherein the at least two hybridization events comprise a first hybridization to a first sequence in the proximity assay reaction products, and a second hybridization to a second sequence in the proximity assay reaction products.

[0264] Embodiment A12. The method of any of embodiments A1-A11, wherein the method comprises comparing the image generated in step (a) with an image of a sample.

[0265] Embodiment A13. The method of embodiment A12, wherein the image of the sample is generated by staining the sample with a microscopic stain.

[0266] Embodiment A14. The method of any of embodiments A1-A13, further comprising removing the sample from the support between steps (b) and (c).

[0267] Embodiment A15. The method of any of embodiments A1-A14, wherein the biological sample is a tissue section.

[0268] Embodiment A16. The method of embodiment A15, wherein the tissue section is a formalin-fixed paraffin-embedded (FFPE) tissue section.

[0269] Embodiment A17. The method of any of embodiments A1-A16, wherein the support is a glass slide.

[0270] Embodiment A18. The method of any of embodiments A1 to A17, wherein the binding agent of step (a) is an oligonucleotide probe, an antibody, or an aptamer.Embodiment B1. A method for analyzing a biological sample, comprising: (a) hybridizing in situ multiple pairs of reporter oligonucleotides to RNA in a biological sample; (b) ligating together in situ any pairs of reporter oligonucleotides that hybridize to adjacent sites to generate ligation products; (c) transferring the ligation products into or onto a support in a manner that preserves the spatial relationship of the ligation products in the sample; (d) detecting the ligation product on the support by hybridization of a labeled probe to the ligation product.

[0271] Embodiment B2. one member of each pair of reporter oligonucleotides has an end that contains a reactive group and the other member has an exonuclease resistant linkage; In step (c), the ligation product becomes tethered to the support via the reactive group; The method of embodiment B1, wherein prior to step (d), the method comprises degrading any unligated reporter oligonucleotides and other single-stranded DNA molecules by exonuclease treatment.

[0272] Embodiment B3. The method of embodiment B1 or B2, wherein at least one member of each pair of reporter oligonucleotides has a tail that does not hybridize to RNA, and in step (d) the labeled probe hybridizes to the tail of the reporter oligonucleotide in the ligation product.

[0273] Embodiment B4. The method of any of embodiments B1-B3, wherein the biological sample is a tissue section.

[0274] Embodiment B5. The method of any of embodiments B1-B4, wherein the labeled probe comprises a complex of a defined number of unlabeled and labeled oligonucleotides hybridized to one another.

[0275] Embodiment B6. Step (d) comprises: (b)(i) hybridizing the ligation product on the support with a first bridging oligonucleotide and a second bridging oligonucleotide, where the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to different sequences in the ligation product; (ii) hybridizing the first bridging oligonucleotide and the second bridging oligonucleotide hybridized to the ligation product with a labeled complex composed of a predetermined number of unlabeled and labeled oligonucleotides hybridized in a complex, the labeled complex hybridizing to both bridging oligonucleotides; (iii) detecting the hybridized labeled complexes with a resolution capable of detecting hybridization of a single labeled complex. In these embodiments, the first bridging oligonucleotide and the second bridging oligonucleotide may hybridize in a "direct" manner, with the 5' end of one bridging oligonucleotide adjacent to the 3' end of the other (with a gap of less than 10 nucleotides, 5, or 4, 3, 2, 1, or 0 nucleotides). Although shown in a complex, these molecules are mirror images, not the same. The bridging molecule may have several binding sites for labeled probes.

[0276] Embodiment B7. the first bridging oligonucleotide and the second bridging oligonucleotide have a tail that does not hybridize to the ligation product; At least some of the unlabeled oligonucleotides in the labeled complex hybridize to the tails of both the first bridging oligonucleotide and the second bridging oligonucleotide; The method of embodiment B6, wherein the complex comprises a defined number of labeled oligonucleotides, the labeled oligonucleotides hybridized to unlabeled oligonucleotides.

[0277] Embodiment B8. The method of any of embodiments B5 to B7, wherein the complex comprises from 4 to 20 unlabeled oligonucleotides and from 8 to 200 labeled oligonucleotides.

[0278] Embodiment B9. The method of any of embodiments B6-B8, wherein the first bridging oligonucleotide has a first stabilizing sequence and the second bridging oligonucleotide has a second stabilizing sequence, and when the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to the ligation product, the first and second stabilizing sequences hybridize to each other.

[0279] Embodiment B10. The method of embodiment B9, wherein the stabilizing sequences are 4-10 bp in length, one stabilizing sequence at the 3' end of the first bridging oligonucleotide and the other stabilizing sequence at the 5' end of the second bridging oligonucleotide.

[0280] Embodiment C1. A method for analyzing a biological sample, comprising: (a) labeling a biological sample with a plurality of conjugates, each of the plurality of conjugates comprising: i. a binding agent that binds to a site or sequence in the sample; and ii. a first oligonucleotide; (b) ligating together in situ a pair of reporter oligonucleotides to generate a reporter probe, the ligation of the reporter oligonucleotides being templated by either i. the first oligonucleotides adjacent to each other, or ii. the ligation product thereof; (c) optionally, moving reporter probes into or onto a support so as to preserve the spatial relationship of proximity assay reaction products in the biological sample; (d) removing unreacted reporter oligonucleotides and other single-stranded DNA molecules by exonuclease treatment or washing, where removing is performed in situ or in or on the support; (e) detecting the reporter probe, either in situ or in or on the support, by hybridization of a labeled probe to the reporter probe.

[0281] Embodiment C2. The method of embodiment C1, wherein the labeled probe comprises a defined nucleic acid structure composed of a predetermined number of unlabeled and labeled oligonucleotides.

[0282] Embodiment C3. The method of embodiment C1 or C2, wherein at least one member of each pair of reporter oligonucleotides has a tail that does not hybridize to the first oligonucleotide or its ligation product, and in step (e) the labeled probe hybridizes to the tail of the reporter oligonucleotide in the reporter probe.

[0283] Embodiment C4. The method of embodiment C3, wherein step (c) is not performed and steps (d) and (e) are performed in situ, and in step (e) the labeled probe is hybridized to the tail of a reporter oligonucleotide in a reporter probe.

[0284] Embodiment C5. Step (c) is carried out: one member of each pair of reporter oligonucleotides has an end containing a reactive group and the other member has a tail that does not hybridize to the first oligonucleotide or its ligation product; In step (c), the reporter probe is tethered to a support via a reactive group; The method of embodiment C3, wherein in step (d), the reporter probe is detected in situ by hybridization of a labeled probe to the tail of a reporter oligonucleotide in the reporter probe.

[0285] Embodiment C6. Step (b) comprises: (b)(i) joining together a first pair of oligonucleotides in situ to generate a first product; (ii) using the first product as a template to join together a pair of reporter oligonucleotides in situ to generate a reporter probe.

[0286] Embodiment C7. The method of embodiment C6, wherein step (d) comprises removing unreacted reporter oligonucleotides and other single-stranded DNA molecules by exonuclease treatment or by washing at a temperature below the Tm of the first product duplex, which is the reporter probe.

[0287] Embodiment C8. The method of any of embodiments C1-C7, wherein the ligation product of (b)(ii) is generated by ligation or a gap-fill / ligation reaction.

[0288] Embodiment C9. The method of any of embodiments C1-C8, wherein the ligation product of (b)(ii) is made using a supported ligation reaction.

[0289] Embodiment C10 The method of embodiment C6, wherein (i) and (ii) are carried out in separate reactions.

[0290] Embodiment C11. The method of embodiment C6, wherein (i) and (a)(ii) are performed in the same reaction, in which the reporter oligonucleotide is prehybridized with the first oligonucleotides and serves as a splint for joining the first oligonucleotides together, and one of the first oligonucleotides serves as a template for ligating the reporter oligonucleotide.

[0291] Embodiment C12. The method of any of embodiments C1-C11, wherein the binding agent of step (a) is an oligonucleotide probe, an antibody, or an aptamer.

[0292] Embodiment C13. The method of any of embodiments C1-C12, wherein the biological sample is a tissue section.

[0293] Embodiment D1. A method for analyzing a biological sample, comprising: (a) performing a proximity assay in situ in a biological sample to generate a proximity assay reaction product; (b) moving the proximity assay reaction products into or onto the support in a manner that preserves the spatial relationship of the proximity assay reaction products in the sample; (c) detecting the proximity assay reaction products on the support; (i) hybridizing the proximity assay reaction product with a first bridging oligonucleotide and a second bridging oligonucleotide, where the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to different sequences in the proximity assay reaction product; and (ii) hybridizing the first bridging oligonucleotide and the second bridging oligonucleotide hybridized to the proximity assay reaction product with a labeling complex composed of a predetermined number of unlabeled oligonucleotides and a predetermined number of labeled oligonucleotides hybridized in the complex, the labeling complex hybridizing to both bridging oligonucleotides, thereby labeling; (d) detecting the hybridized labeled complexes with a resolution capable of detecting hybridization of a single labeled complex.

[0294] Embodiment D2. the first bridging oligonucleotide and the second bridging oligonucleotide have a tail that does not hybridize to the proximity assay reaction product; At least some of the unlabeled oligonucleotides in the labeled complex hybridize to the tails of both the first bridging oligonucleotide and the second bridging oligonucleotide; The method of embodiment D1, wherein the labeled complex comprises a defined number of labeled oligonucleotides, the labeled oligonucleotides being hybridized to the labeled oligonucleotide.

[0295] Embodiment D3. The method of embodiment D1 or D2, wherein the labeled complex comprises between 4 and 20 labeled oligonucleotides and between 8 and 200 labeled detection oligonucleotides.

[0296] Embodiment D4. The method of any of embodiments D1-D3, wherein the first bridging oligonucleotide has a first stabilizing sequence and the second bridging oligonucleotide has a second stabilizing sequence, and when the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to the proximity assay reaction product, the first and second stabilizing sequences hybridize to each other.

[0297] Embodiment D5. The method of embodiment D4, wherein the stabilizing sequences are 4-10 bp in length, one stabilizing sequence at the 3' end of the first bridging oligonucleotide and the other stabilizing sequence at the 5' end of the second bridging oligonucleotide.

[0298] Embodiment D6 The method of any of embodiments D1-D5, wherein the biological sample is a tissue section.

[0299] Embodiment D7. The method of any of embodiments D1-D6, wherein in step (b) the sequences to which the first bridging oligonucleotide and the second bridging oligonucleotide hybridize in the proximity assay reaction product are combined into a single molecule in the proximity assay of (a).

[0300] Embodiment D8. The proximity assay comprises: (b)(i) binding together in situ a pair of first oligonucleotides to generate a first product, wherein the first oligonucleotides bound together are each part of a binding agent-oligonucleotide conjugate bound to the sample; (ii) using the first product as a template to join together pairs of reporter oligonucleotides in situ to generate a reporter probe; The method of any of embodiments D1-D7, wherein in step (c), the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to a reporter probe.

[0301] Embodiment D9. The method of embodiment D8, wherein at least one member of each pair of reporter oligonucleotides has a tail that does not hybridize to the first product, and the labeled complex hybridizes to the tail of the reporter oligonucleotide in the reporter probe.

[0302] Embodiment D10. The method of any of embodiments D1-D9, further comprising treating the sample or support with an exonuclease between steps (a) and (c) to remove unreacted single-stranded DNA molecules.

[0303] Embodiment D11. The method of any of embodiments D1 to D10, wherein the binding agent used in the proximity assay of step (a) is an oligonucleotide probe, an antibody, or an aptamer.

[0304] Embodiment E1. A method for analyzing a biological sample, comprising: (a) performing a proximity assay in situ in a biological sample to generate a proximity assay reaction product; (b) separating the proximity assay reaction products from (i) hybridizing the proximity assay reaction product with a first bridging oligonucleotide and a second bridging oligonucleotide, where the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to different sequences in the proximity assay reaction product; and (ii) in situ labeling by hybridizing the first bridging oligonucleotide and the second bridging oligonucleotide hybridized to the proximity assay reaction product with a labeling complex consisting of a predetermined number of unlabeled oligonucleotides and a predetermined number of labeled oligonucleotides hybridized in a complex, the labeling complex hybridizing to both bridging oligonucleotides; (c) detecting the hybridized labeled complexes with a resolution capable of detecting hybridization of a single labeled complex.

[0305] Embodiment E2. the first bridging oligonucleotide and the second bridging oligonucleotide have a tail that does not hybridize to the proximity assay reaction product; at least some of the unlabeled oligonucleotides in the labeled complex hybridize to the tails of both the first bridging oligonucleotide and the second bridging oligonucleotide; The method of embodiment E1, wherein the labeled complex comprises a defined number of labeled oligonucleotides, wherein the labeled oligonucleotides are hybridized to the labeled oligonucleotide.

[0306] Embodiment E3. The method of embodiment E1 or E2, wherein the labeled complex comprises between 4 and 20 labeled oligonucleotides and between 8 and 200 labeled detection oligonucleotides.

[0307] Embodiment E4. The method of any of embodiments E1-E3, wherein the first bridging oligonucleotide has a first stabilizing sequence and the second bridging oligonucleotide has a second stabilizing sequence, and when the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to the proximity assay reaction product, the first and second stabilizing sequences hybridize to each other.

[0308] Embodiment E5. The method of embodiment E4, wherein the stabilizing sequences are 4-10 bp in length, one stabilizing sequence is at the 3' end of the first bridging oligonucleotide and the other stabilizing sequence is at the 5' end of the second bridging oligonucleotide.

[0309] Embodiment E6 The method of any of embodiments E1-E5, wherein the biological sample is a tissue section.

[0310] Embodiment E7. The method of any of embodiments E1-E6, wherein in step (b) the sequences to which the first bridging oligonucleotide and the second bridging oligonucleotide hybridize in the proximity assay reaction product are combined into a single molecule in the proximity assay of (a).

[0311] Embodiment E8. The proximity assay comprises: (b)(i) binding together in situ a pair of first oligonucleotides to generate a first product, wherein the first oligonucleotides bound together are each part of a binding agent-oligonucleotide conjugate bound to the sample; (ii) using the first product as a template to join together pairs of reporter oligonucleotides in situ to generate a reporter probe; The method of any of embodiments E1-E6, wherein in step (b), the first bridging oligonucleotide and the second bridging oligonucleotide hybridize to a reporter probe.

[0312] Embodiment E9. The method of embodiment E8, wherein at least one member of each pair of reporter oligonucleotides has a tail that does not hybridize to the first product, and the labeled complex hybridizes to the tail of the reporter oligonucleotide in the reporter probe.

[0313] Embodiment E10. The method of any of embodiments E1-E9, further comprising treating the sample with an exonuclease prior to step (b) to remove unreacted single-stranded DNA molecules.

[0314] Embodiment E11. The method of any of embodiments E1-E10, wherein the binding agent used in the proximity assay of step (a) is an oligonucleotide probe, an antibody, or an aptamer.

[0315] In embodiments A-G, releasing may be performed by contacting the biological sample with the support so that the biological sample faces the support (i.e., by sandwiching the sample between two supports) and then heating the sample.

[0316] In any of the embodiments A-G, the planar sample may be generated by passing a suspension of cells through a filter, with the cells being retained on the filter. The cells on the filter are a planar support.

[0317] Embodiment G1. A method for analyzing a suspension of cells, comprising: (a) filtering the suspension of cells through a porous capillary membrane, thereby distributing the cells on the membrane, (b) placing the membrane on a planar support with the cell side of the membrane facing the support, (c) transferring nucleic acids from the cells into or onto the support so as to preserve the spatial relationship of the nucleic acids in the cells, (d) removing the porous capillary membrane and the cells from the support, and (e) spatially analyzing the nucleic acids transferred to the support.

[0318] Embodiment G2. The method of embodiment G1, further comprising between steps (a) and (c) performing a proximity assay in situ on one or more pairs of binding agent-oligonucleotide conjugates bound to the cells to generate proximity assay reaction products in or on the cells, wherein the nucleic acid transferred in step (c) and analyzed in step (e) comprises the proximity assay reaction products.

[0319] Embodiment G3. The method of embodiment G2, wherein step (e) comprises (i) labelling the proximity assay reaction products transferred into or onto the support, and (ii) imaging the support to generate an image of sites where the proximity assay reaction products are bound in or on the support.

[0320] Embodiment G4. The method of embodiment G2 or G3, wherein the proximity assay comprises any combination of ligation, primer extension, and gap-fill / ligation reactions involving oligonucleotides of the binder-oligonucleotide conjugate.

[0321] Embodiment G5. The method of any of embodiments G1-G4, wherein the planar support of (b) comprises an array of spatially barcoded capture oligonucleotides, step (c) comprises hybridizing the transferred nucleic acid to the spatially barcoded capture oligonucleotides, and step (e) comprises extending the capture oligonucleotides using the transferred nucleic acid as a template and sequencing copies of the primer extension template to generate sequence reads.

[0322] Embodiment G6. The method of embodiment G5, further comprising mapping the sequence reads to sites on the support using spatial barcodes in the sequence reads.

[0323] Embodiment G7. The method of any of embodiments G1 to G6, wherein the transferring step (c) is carried out by electrophoresis or diffusion.

[0324] Embodiment G8. The kit of any of embodiments G1-G7, wherein the porous capillary membrane is a porous anodized aluminum oxide membrane.

[0325] Embodiment G9. The method of any of embodiments G1-G8, wherein step (a) is carried out by (i) placing a suspension of cells on a porous capillary membrane and (ii) applying a force to move a liquid component of the suspension through the membrane.

[0326] Embodiment G10. The method of embodiment G7, wherein the force is an active force selected from centrifugal force, negative pressure and positive pressure, or a passive force selected from capillary action and evaporation.

[0327] Embodiment G11. The method of any of embodiments G1-G10, further comprising washing the porous capillary membrane between steps (d) and (e).

[0328] Embodiment G13. The method of any of embodiments G1-G12, wherein the inner diameter of the pores in the membrane is in the range of 2 nm to 500 nm.

[0329] Embodiment G14. The method of any of embodiments G1-G13, wherein the average distance between the centers of adjacent pores in the membrane is in the range of 50 nm to 1000 nm.

[0330] Embodiment G15. The method of any of embodiments G1-G14, wherein the average distance between the edges of adjacent pores in the membrane is in the range of 10 nm to 500 nm.

[0331] Embodiment G16. The method of any of embodiments G1 to G15, wherein the suspension of cells comprises blood cells, immune cells, single cells separated from one another by trypsinization, or the cells are cultured as a suspension.

[0332] Embodiment G17. The method of embodiment G2, wherein each binder-oligonucleotide conjugate comprises i. a binder that binds to a site or sequence in the sample, and ii. a first oligonucleotide, and the proximity assay comprises binding together in situ a pair of reporter oligonucleotides to generate a reporter probe, wherein binding of the reporter oligonucleotides is templated by either i. the first oligonucleotides that are in proximity to each other, or ii. their ligation product, and the reporter probe is transferred to the support in step (c), and step (e) comprises detecting the reporter probe on the support by hybridization of a labeled probe to the reporter probe.

[0333] Embodiment G18. The method of embodiment G17, wherein the method further comprises removing unreacted reporter oligonucleotides and other single-stranded DNA molecules by exonuclease treatment or washing.

[0334] Embodiment G19. The method of embodiment G17 or G18, wherein at least one member of each pair of reporter oligonucleotides has a tail that does not hybridize to the first oligonucleotide or its ligation product, and in step (e) the labeled probe hybridizes to the tail of the reporter oligonucleotide in the reporter probe.

[0335] Embodiment G20. The method of any of embodiments G17 to G19, wherein one member of each pair of reporter oligonucleotides has an end containing a reactive group and the other member has a tail that does not hybridize to the first oligonucleotide or its ligation product, and in step (c) the reporter probe is tethered to the support via the reactive group, and in step (e) the reporter probe is detected by hybridization of a labeled probe to the tail of the reporter oligonucleotide in the reporter probe. EXAMPLES

[0336] In order to further illustrate some embodiments of the present invention, the following specific examples are provided, it being understood that they are provided to illustrate examples of the invention and should not be construed as limiting its scope in any way.

[0337] Example 1 This embodiment provides an assay that includes converting information about closely located biomolecules into DNA and transferring the DNA to a planar support. The DNA on the planar support is detected to identify information about closely located biomolecules or to detect a single biomolecule that targets two distinct epitopes or loci. Thus, in these methods, information about closely located biomolecules is converted into DNA molecules, which are then analyzed in a streamlined, multiplexed format.

[0338] This example describes the implementation of PA to transfer protein information to DNA. For example, using PA ensures specificity and transfer of both RNA and DNA molecules from PA to one reporter molecule format (i.e., DNA). This design allows short oligos to be used for proximity ligation, ensuring the requirement of close proximity in PA assays. These shorter oligonucleotides are then converted in a second step to longer oligonucleotides that allow hybridization-based barcode reading.

[0339] In this embodiment, detection is designed to be a programmable cascade of a defined number of detection fluorophores.By transferring nucleic acid reaction products to a planar support, it becomes easier to perform single molecule detection with lower background compared to analysis in tissues where background fluorescence is high.Imaging time is also reduced because there is no need or reduced need to image z-stacks when imaging molecules on a planar surface.

[0340] In this example, instead of using rolling circle replication, where the exact amplification level is difficult to control, the actual number of nucleic acid reaction products generated during PA is detected. Furthermore, the controlled hybridization reaction chemistry, where the exact number of fluorophores is added to each target molecule, results in more uniform detection of target single molecules. Thus, spatial detection of protein and protein interactions without RCA allows for analysis / detection of smaller fluorescent molecules at higher densities. After each detection cycle, the labeled detection oligonucleotides are washed away, leaving only individual reporter molecules on the surface, avoiding physical crowding on the surface.

[0341] In this example, the following protocol is followed for analyzing planar biological samples.

[0342] The tissue section is immobilized on a solid support. The information about the location of the protein is converted into a DNA molecule by ligating an oligonucleotide conjugated to an antibody. For each protein, protein modification, or protein / protein interaction detected, two antibodies are used. An antibody mixture containing multiple pairs of antibodies is incubated to bind to each target protein in the tissue.

[0343] The antibody pairs are designed such that one oligonucleotide conjugated to one antibody of the pair has a free 3' end, and the other oligonucleotide conjugated to the other antibody of the pair has a free 5' end. Unbound antibody is washed away, and the antibody is optionally fixed to tissue. Fixing the antibody to tissue helps it to withstand subsequent washes and incubations.

[0344] A splint complementary to the pair of oligonucleotides is then added. A ligase is then added, allowing ligation of the oligonucleotides that form the pair of antibodies when the pair of antibodies are in close proximity. The splint is designed to stably hybridize to the two oligonucleotides conjugated to the two antibodies that are in close proximity.

[0345] A splint can also be added, allowing combinatorial ligation of one antibody to many other antibodies to look for specific potential interactions or protein modifications. Alternatively, all 3' conjugated antibodies can be ligated to all 5' conjugated antibodies. However, the risk of getting significant noise / background is higher, since many proteins are in close proximity by chance, not by protein-protein interactions. In this case, the signal-to-noise ratio can be determined by comparing counts from different cell populations and looking for statistically significant variations in the interaction patterns between cell populations. The signal from detection using two binders targeting the same protein and two binders targeting interactions involving the same protein can also be measured and used as an internal reference.

[0346] The splint is washed away and a reporter probe is added. The reporter probe can be designed to hybridize to the ligated oligonucleotides from the proximity antibodies. Specific reporter probes that hybridize to RNA targets can also be designed. The reporter probes are designed to form reporter polynucleotides with barcodes that correspond to the ligated oligonucleotides to which they hybridize or / and the RNA molecules to which they hybridize. Thus, the sequences of the barcodes in the reporter probes and the resulting reporter polynucleotides contain information about the target protein and the target RNA.

[0347] The reporter probe pair is designed to have one ligatable end each. One of the probes is equipped with an affinity moiety. Optionally, the unligated end of the reporter polynucleotide can be modified to be exonuclease resistant. The affinity moiety is advantageously derivatizable, such as a click chemistry group. The affinity moiety can also be a DNA sequence that can be ligated using a specific sequence. The affinity moiety can be a binding member of a specific binding pair that specifically binds to a member present on a planar support.

[0348] Upon hybridization to ligated oligonucleotides and / or RNA molecules in tissues, the reporter probes contain a combination of barcodes that together constitute a unique barcode designed to be decoded by detection of the reporter polynucleotide.

[0349] The steps of ligating the splint and the reporter probe can be carried out in the same reaction. This means two ligation sites for the protein molecule, which may reduce efficiency, but on the other hand, only one ligation step would be needed, which would increase efficiency. The ligation would also need to be specific for the RNA molecule under the same conditions.

[0350] Excess reporter probe is washed away. The reporter probe in the tissue is transferred to a solid phase and attached using the affinity moiety on the reporter polynucleotide. To facilitate the transfer of the reporter polynucleotide to the planar support, the reporter polynucleotide can be released from their target using denaturing conditions, for example, with chemicals such as NaOH, formamide, urea, guanidine or urea, and temperature. Release can also be facilitated by cleaving the cleavable linker between the antibody and the conjugated oligonucleotide.

[0351] Alternatively, the release can be mediated enzymatically using RNA to degrade the RNA target, thereby designing an oligonucleotide conjugated to an antibody with a uracil base that can be degraded using uracil-DNA glycosylase, releasing the reporter probe bound to the RNA. Each release chemistry is selected so that it is compatible with the affinity chemistry on the surface and the mechanism of transfer to the surface.

[0352] The planar support can be either the same solid support on which the tissue section is immobilized, or a second support provided on top of the tissue. In the former case, the affinity reaction needs to be inducible, since otherwise the probe would block the surface during hybridization when excess probe is added. One example of such an affinity reaction uses click chemistry, which requires copper to create a covalent bond. In another example, ligation is performed on oligonucleotides immobilized on a surface using a template splint, thereby facilitating covalent ligation of a reporter polynucleotide to the oligonucleotide immobilized on the solid support.

[0353] Alternatively, a separate planar support can be used to transfer the reporter polynucleotides from the tissue. Transfer of the reporter polynucleotides from the tissue to the planar support can be accelerated using electrophoresis.

[0354] In one example, instead of using a planar solid support, tissue is immobilized in a clearing gel matrix support after ligation of reporter probes.One of the reporter probes has a moiety that immobilizes reporter polynucleotide in the gel.After polymerization of the gel, tissue components can be removed from the gel without damaging DNA polynucleotide.

[0355] Then, single molecule identification of the immobilized reporter polynucleotide is performed.The reporter polynucleotide contains a given set of barcodes to be detected.For example, if two colors are analyzed per detection cycle and 16 cycles are performed, 32 different barcodes are read.Barcodes can be designed so that each reporter polynucleotide has a unique set of barcodes from the combination of 32 barcodes.

[0356] Detection probes are added in multiple cycles, labeling a different barcode(s) in each cycle, thereby detecting the binary sequence of barcodes present in each reporter oligonucleotide. Each cycle includes labeling, washing, imaging, and removal of detection probe before the next cycle begins.

[0357] The detection scheme can be designed such that in each cycle, a pair of bridge probes are first hybridized to each barcode and converted into a longer oligonucleotide for detection (Figure 5). The bridge probes can be advantageously designed to be stabilized to each other upon hybridization by weak complementary hybridization, stacking hybridization or enzymatic ligation, and not individually stable.

[0358] After hybridization of the bridging probes, the detection probes are added. The detection probes require the presence of both bridging probes in close proximity to form a stable hybridization. This ensures that background adsorption of individual bridging probes does not create background. In this example, each bridging probe can hybridize to three detection probes. Each detection probe is designed to be able to hybridize to multiple (e.g., nine) labeled probes. Each detection probe individually generates a signal that is too weak to generate a signal above background, but three detection probes each labeled with nine labeled probes aggregate a total of 27 labels designed to create a signal above background (Figure 5). The detection probes and labeled probes can be prehybridized together and added in the same step.

[0359] Considering that a pair of bridging probes is attached to one reporter polynucleotide, multiple detection probes, each hybridized to several labeling probes, need to be hybridized to a pair of bridging probes to register a signal above background. This design ensures that signal generation specificity is maintained. Individual bridging probes do not generate background when they are attached to a surface, and individual detection or labeling probes do not generate enough signal to generate a signal above background. Multiple labels with different fluorophores can be used so that multiple barcodes can be detected in one labeling cycle. Hybridization chemistry is designed to have a defined number of fluorophores for each target molecule.

[0360] Example 2 In this example, an antibody oligonucleotide conjugate is used. Oligonucleotide A is conjugated to antibody A to produce conjugate A. Protein A in tissue oligonucleotide A' is hybridized to oligonucleotide A before conjugating conjugate A to its target. Oligonucleotide A' also carries biotin at the 5' end, and the fluorophore at the 3' end has an additional sequence A'1 that is not complementary to oligonucleotide A. Conjugate A hybridized to oligonucleotide A' is bound to an FFPE tissue section immobilized on a glass slide and run through a suitable sample preparation, including, for example, antigen retrieval and blocking. The tissue section is then washed and a streptavidin-coated capture planar support is placed facing the tissue section. The slide with the tissue and planar support is held in place and the slide is placed in an oven to raise the temperature above the melting temperature of oligonucleotide A and oligonucleotide A'. Oligonucleotide A' is then captured on the planar support using streptavidin-biotin interactions. The slide can be imaged using fluorescence microscopy and the attached fluorescent molecules can be used to detect oligonucleotide A. The pattern on the planar support represents a mirror image of the tissue.

[0361] Example 3 Displacement of reporter oligonucleotides from antibody conjugates and detection on the capture surface using immunofluorescence Antibody-oligonucleotide conjugation: Antibodies against keratin 8 (catalog no. 904804, Biolegend) and keratin 18 (catalog no. 628402, Biolegend) were buffer exchanged into DPBS using a 0.5 mL Zeba™ spin desalting column 7K MWCO and concentrated to 1 mg / mL using an Amicon® Ultra-0.5 centrifugal filter 10K MWCO device. DBCO-NHS-ester (catalog no. 761524, Sigma-Aldrich) was dissolved in DMSO and diluted to 2 mM. A 15-fold molar excess of DBCO-NHS-ester was added to the antibody and the reaction was incubated at room temperature for 45 min protected from light. 1 M Tris-HCl (pH 8) was added to a final concentration of 30-100 mM and the reaction was incubated at room temperature for 5 min. To remove unreacted DBCO-NHS esters, 0.5 mL Zeba™ spin desalting columns 7K MWCO (Thermo Scientific, Cat. No. 89882) equilibrated in DPBS were used according to the manufacturer's instructions. A 2.5-fold molar excess of azide-modified DNA oligonucleotides was added to the DBCO-activated antibody. The reaction was incubated for at least 60 h in a refrigerator (2-8 °C). Successful conjugation was verified by polyacrylamide gel electrophoresis, staining the conjugates with SYBR Gold nucleic acid gel stain (S11494, Invitrogen) and InstantBlue Coomassie protein stain (Abcam, ab119211). The antibody-oligonucleotide conjugates were diluted to 0.15 μg / μL in DPBS containing 0.1% BSA and 0.02% NaN3.

[0362] Tissue preparation: Tissue microarrays containing cores from FFPE blocks were sectioned into 4 μm thick slices and placed on TOMO glass slides (Matsunami). After baking, slides were deparaffinized in xylene (2 times for 5 min) and hydrated through a graded series of ethanol to deionized water. Endogenous peroxidase was blocked with 3% H2O2 in PBS for 10 min at room temperature. Slides were rinsed once in PBS. For antigen retrieval, antigen retrieval buffer, citrate buffer, pH 6.0 [Abcam, ab93678] was used for 50 min at 98°C. Slides were rinsed once in PBS. Barriers were created by drawing with an ImmEdge™ hydrophobic barrier pen. Finally, slides were rinsed in TBS containing 0.05% Tween-20.

[0363] Staining: Avidin blocking buffer was prepared as follows: 1× TBS, 0.05% Tween-20, 0.25 mg / mL BSA, 0.5 mg / mL salmon sperm DNA (Sigma), avidin 5 μg / mL.

[0364] Avidin blocking buffer was used to cover the TMA and the slides were incubated for 1 h at room temperature in a humidified chamber, followed by two 2 min washes in TBS containing 0.05% Tween-20.

[0365] Biotin blocking buffer was prepared as follows: 1× TBS, 0.05% Tween-20, 0.25 mg / mL BSA, 0.5 mg / mL salmon sperm DNA (Sigma), biotin 12.5 μg / mL, 10 mg / mL dextran sulfate.

[0366] Biotin blocking buffer was used to cover the TMA and the slides were incubated for 1 hour at room temperature in a humidified chamber.

[0367] Keratin-18 antibody was diluted to 0.75ng / μL in biotin blocking solution, then used to cover the TMA and the slides were incubated for 1 hour at room temperature in a humidified chamber, followed by three washes in TBS containing 0.05% Tween-20 at 45°C for 5 minutes.

[0368] Biotin blocking buffer was once again used to cover the TMA and the slides were incubated for 1 hour at room temperature in a humidified chamber.

[0369] Hybridization buffer was prepared as follows: 10 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 0.5 mg / mL BSA, 250 mM NaCl, 0.05% Tween-20, water to final volume.

[0370] DNA oligos (22 bp, biotinylated and containing a fluorophore) were diluted to 50 nM in hybridization buffer and incubated on the TMA for 30 min at 37° C. in a humidified chamber, followed by three washes for 5 min at 45° C. in TBS containing 0.05% Tween-20.

[0371] Avidin coating of glass coverslips: Glass coverslips: 200 nm biotin-derivatized linear polycarboxylate hydrogel, medium charge density (XanTec bioanalytics GmbH).

[0372] The coverslips were rinsed once with PBS and incubated in 0.1 mg / mL avidin (in PBS) for 1 hour at room temperature, then washed three times in PBS.

[0373] Transfer: The tissue slide and cover slip were incubated in 10 mM NaAc (pH 5.5) solution for 15 minutes. The two glasses were aligned and brought together without creating air bubbles, and then incubated in a humidified chamber at 60° C. for 75 minutes. Finally, the cover slip was carefully detached from the slide glass.

[0374] Mounting: The transferred coverslip was incubated with biotinylated fluorescent 1 μm beads for 5 min at room temperature (for focusing purposes). It was then washed 3 times for 2 min in TBS containing 0.05% Tween-20. Finally, the tissue slide and the transferred coverslip were mounted separately using EverBrite Hardset mounting medium.

[0375] Imaging: Slides were imaged on a 3D Histech slide scanner according to the manufacturer's instructions.

[0376] result: The assay was designed to target keratin-18 in samples with a 1 mm morphology of the FFPE fixed cell line MCF7. Cells could be visualized on the original tissue slide (Figure 7A) and individual cell imprints (products of transfer of ssDNA fluorescent oligos) were also visible on the capture surface (Figure 7B), demonstrating transfer of the sample with retained spatial resolution.

[0377] Example 4 Detection of PLA-generated reporter probes by hybridization chain reaction (HCR) on the capture surface after transfer Antibody and tissue preparation: As above.

[0378] TMAs containing human tonsil, human placenta, MCF7 cells and MOLT4 cells, as well as FFPE DAUDI cells and 0.6 mm cores of MDA-MB231 as described in FIG.

[0379] Proximity Ligation Assay (PLA) Tissue blocking: Avidin blocking buffer was prepared as follows: TBS, 0.05% Tween-20, 0.25 mg / mL BSA, 0.5 mg / mL salmon sperm DNA (Sigma), avidin 5 μg / mL.

[0380] Avidin blocking buffer was used to cover the TMA sections and the slides were incubated for 1 hour at room temperature, followed by two 2-minute washes in TBS containing 0.05% Tween-20.

[0381] Biotin blocking buffer was prepared as follows: TBS, 0.05% Tween-20, 0.25 mg / mL BSA, 0.5 mg / mL salmon sperm DNA (Sigma), biotin 12.5 μg / mL.

[0382] Biotin blocking buffer was used to cover the TMA and the slides were incubated for 30 minutes at room temperature. The slides were rinsed once in TBS containing 0.05% Tween-20.

[0383] Antibody incubation: A pair of antibody-oligonucleotide conjugates was diluted to 1 μg / mL of each antibody in biotin blocking buffer. The diluted conjugates were applied to the slides. The slides were incubated overnight at 4° C. The slides were washed twice for 5 min in TBS containing 0.05% Tween-20.

[0384] Proximity Ligation Assay (PLA) to Create Ligated Reporter Probes: Two target oligonucleotides were ligated by adding 125 nM splint, 0.04 U / μL T4 DNA ligase (ThermoScientific), 10 mM Tris-acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 0.5 mg / mL BSA, 200 mM NaCl, and 0.05% Tween-20. Reactions were incubated for 30 min at 37° C. in a humidified chamber. For the no-ligation negative control, this splint template ligation step was omitted. Slides were washed twice for 5 min in TBS with 0.05% Tween-20.

[0385] Reporter oligonucleotides, one containing biotin and one containing Alexa647, were diluted to 33 nM in 10 mM Tris acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 0.5 mg / mL BSA, 250 mM NaCl, and 0.05% Tween-20 and then added to the slide to hybridize to the first ligation product. The hybridization reaction was incubated for 30 minutes at 37° C. in a humidified chamber. The slides were then washed twice for 5 minutes in TBS containing 0.05% Tween-20. Reporter oligonucleotides were then ligated by adding 0.04 U / μL T4 DNA ligase (ThermoScientific), 10 mM Tris acetate, 10 mM magnesium acetate, 50 mM potassium acetate, 0.5 mg / mL BSA, 200 mM NaCl, and 0.05% Tween-20 during 30 min incubation at 37° C. in a humidified chamber. Slides were washed twice for 2 min in TBS containing 0.05% Tween-20.

[0386] Unligated reporter oligonucleotides were digested and the ligated reaction product / reporter probe was prepared for release using a nuclease mix containing 0.01 U / μL USER (New England Biolabs), 0.1 U / μL lambda exonuclease (New England Biolabs), 1× rCutSmart buffer (New England Biolabs) and 0.05% Tween-20. Slides were washed twice for 5 min in TBS with 0.05% Tween-20.

[0387] Coating of glass coverslips: As above.

[0388] Transfer: The tissue slide and cover slip were incubated in 10 mM NaAc (pH 5.5) solution for 15 minutes. The two glasses were aligned and brought together without creating air bubbles, and then incubated in a humidified chamber at 60° C. for 60 minutes. Finally, the cover slip was carefully detached from the slide glass.

[0389] HCR detection of reporter molecules on coverslips: The area where migration should occur was delineated with an ImmEdge pen (Vector Laboratories). Coverslips were incubated with biotin-labeled microparticles (0.2 μM, yellow-green fluorescent (505 / 515)) in 2×SSC (Sigma) for 15 min at room temperature. Coverslips were washed three times for 2 min with 2×SSC containing 0.1% Tween-20. Probes with HCR initiator sequences that recognize the reaction products / reporter probes were diluted to 10 nM in 4×SSC containing 20% ​​ethylene carbonate and 0.1% Tween-20 and added to the coverslips. Coverslips were incubated for 1 h at room temperature in a humidified chamber. Coverslips were washed twice for 5 min in 2×SSC containing 0.1% Tween-20. HCR was performed as previously described by Choi, Beck and Pierce 2014 (ACS Nano 2014, 8, 5, 4284-4294). Briefly, HCR hairpin probes with ATTO565 were individually diluted to 0.5 μM in 40 μL of 5×SSC, incubated at 95° C. for 5 min, and then allowed to cool at room temperature for 10 min. The two hairpin probes were then mixed and diluted to 10 nM in 5×SSC with 0.1% Tween-20. The HCR hairpin probe mixture was applied to the coverslip and the reaction was allowed to proceed for 3 h at room temperature in a humidified chamber protected from light. The coverslips were washed once with 2×SSC with 0.1% Tween-20 and once with TBS. The coverslips were mounted on SlowFade Diamond Antifade Mountant (Invitrogen) and TOMO glass slides (Matsunami).

[0390] Imaging: A 2.5 x 2.5 mm area of ​​the coverslip was imaged by epifluorescence microscopy. The beads were imaged with FITC at an exposure time of 25 ms (data not shown) and HCR detection of the reporter probe was imaged with TRITC at an exposure time of 1 s (Figure 9).

[0391] Results: A PLA assay was performed using one antibody targeting keratin 8 and one targeting keratin 18. This assay was used to analyze a tissue microarray containing six features of which two were shown to be clearly positive (Figure 9). Results are consistent with references.

[0392] Example 5 Detection of keratins 8 and 18 using PLA and readout after transfer of reporter probes to the capture surface using flow cell single molecule sequencing Antibody and tissue preparation: As above.

[0393] TMAs containing human tonsil, human placenta, MCF7 cells and MOLT4 cells, as well as FFPE DAUDI cells and 0.6 mm cores of MDA-MB231 as described in FIG.

[0394] Proximity ligation assay: As above.

[0395] Avidin coating of glass coverslips: As above.

[0396] Transfer: The tissue slide and cover slip were incubated in 10 mM NaAc (pH 5.5) solution for 15 minutes. The two glasses were aligned and brought together without creating air bubbles, and then incubated in a humidified chamber at 60° C. for 75 minutes. Finally, the cover slip was carefully detached from the slide glass.

[0397] Flow cell mounting: Coverslips were rinsed twice with ultrapure water and then mounted in a Bioptechs FCS2 chamber according to the manufacturer's instructions.

[0398] Sequencing: Sequencing was performed by repeatedly introducing labeled oligonucleotides through the flow cell. The chemistry of the present invention required that three different oligo solutions be introduced sequentially in each cycle: a bridging probe, a labeling probe, followed by a fluorescently labeled detection probe. Washes were performed between each oligo mixture. Sequencing was performed with a flow cell of approximately 0.5 cm in each cycle. 2 The area was imaged.

[0399] In this setup, a Fluigent fluidics system (Flow EZ™ 2000) was used to flow reagents in a controlled manner across the flow cell and moving surface. All reagents were injected at a flow rate of 200 μL / min. The flow rate for all wash steps was set to 800 μL / min.

[0400] Beads for field-of-view (FOV) alignment (biotin-labeled microparticles, 0.2 μM, yellow-green fluorescent (505 / 515)) were diluted 1:20,000 in 2× SSC from the original 1% stock suspension, added manually, and incubated for at least 10 min before starting the fluidics system.

[0401] Beads were imaged in FITC with an exposure time of 100 ms and reporter molecules, when labeled with Alexa647N, were imaged in Cy5 with an exposure time of 1000 ms.

[0402] After imaging the beads, non-specific binding was minimized by incubating with 400 μL of blocking buffer (1% biotinylated bovine serum albumin (BSA), 2×SSC) for 30 min at room temperature. Excess BSA was removed by washing with a wash buffer containing salt and detergent using continuous flow.

[0403] Bridge-oligo pairs were incubated at a final concentration of 10 nM in 400 μL hybridization buffer (4×SSC, 0.1% Tween, 30% ethylene carbonate) for a minimum of 1 h at room temperature unless otherwise stated. Hybridization reactions were terminated by washing with 4 mL of wash buffer containing salt and detergent for 5 min using continuous flow.

[0404] A mixture of up to five labeled probes was hybridized at a final concentration of 10 nM of each probe in hybridization buffer (30% ethylene carbonate, 0.1% Tween, 4x SSC) for 30 min at room temperature. The hybridization reaction was stopped by washing for 5 min with 4 mL of wash buffer containing salt and detergent using continuous flow.

[0405] Fluorescently labeled detection probes were then hybridized to the labeled probes in hybridization buffer (30% ethylene carbonate, 0.1% Tween, 4xSSC) for 15 min at room temperature. The surface was then washed for 5 min with 4 mL of wash buffer containing salt and detergent using continuous flow to remove unbound / non-specific oligos and probes.

[0406] The signal is detected by imaging the surface in a channel that matches the fluorescence of the detection probe.

[0407] After signal detection, stripping was performed with organic solvents or ionic compounds (e.g., DMSO or NaOH) for a minimum of 10 min under continuous flow. After stripping, the surface was washed with 4 mL of wash buffer containing salt and surfactant for 5 min using continuous flow.

[0408] Sequencing hardware: The sequencing system was built around an inverted microscope (Nikon Ti2-E) equipped for wide-field epifluorescence imaging, and a pressure-driven flow control system (Fluigent Flow EZ2000 and Fluigent FLOW UNIT L) with two 11-port rotary valves (Fluigent M-SWITCH) connected in series.

[0409] The two systems were controlled using custom scripts running on dedicated software associated with each system, and synchronization between the two systems was achieved using a bidirectional TTL interface.

[0410] The microscope was equipped with a 60x oil immersion objective (Nikon CFI Plan Apochromat Lambda D 60X Oil) and a sCMOS camera (Hamamatsu ORCA-Flash4.0LT). Three fluorescent filter sets were used for imaging in the described experiments: Semrock LED-Cy5-A (herein referred to as Cy5) for imaging Alexa 647N and ATTO647N, Semrock LED-TRITC-A (herein referred to as TRITC) for imaging ATTO 565, and LED-FITC-A (herein referred to as FITC) for imaging reference beads. The light source used was a CoolLED pE-800, with the 550 nm and 635 nm LEDs switched on 100% for imaging with the TRITC and Cy5 channels, respectively, and the 470 nm LED switched on 1% for imaging reference beads with the FITC channel.

[0411] Image analysis: Sequencing image data appears as diffraction-limited bright spots on a dark background over several cycles of imaging, as shown in Figure 10. Three sets of images are acquired, corresponding to Cy5, TRITC and FITC imaging channels. Cy5 and TRITC channels contain sequencing spots, and FITC contains reference beads for image alignment. The image analysis method for detecting fluorescent barcode information consisted of several steps. First, detect and segment the spots in Cy5 and TRITC channels, as well as the beads in FITC channel. A circle detection algorithm adjusted to the size of the spots is used to segment the spots and beads. The beads detected for all different cycles are used to align the cycle data. The spot images are pre-processed to correct for non-uniformity of foreground and background illumination. After correcting for non-uniform illumination, spot features such as position, fluorophore number, etc. are extracted. The alignment information obtained using the beads is used to align the spots in the corresponding image cycles. The barcode information, i.e., molecules on or off over all different imaging cycles, is detected using a neighborhood search of the spots with the aligned spot data. The barcode information for Cy5 and TRITC is combined to obtain barcodes in the two imaging channels. The barcode information is exported in Feather format using Pandas software, which is processed in the latter part of the analysis. In addition to the barcode information, other auxiliary information to check the quality of the data and analysis such as alignment quality metrics are obtained. The entire analysis is performed in Python software using image and data analysis libraries such as Numpy, Scipy, and OpenCV.

[0412] Data analysis: The summary tables (feather format files) obtained in the previous step, containing information on the fluorescent spots identified in each field and each cycle, were imported into R via the Arrow and DataTable packages, and downstream analyses were performed within the R environment. Graphical presentation of the results was performed using the ggplot package.

[0413] The analysis was divided into two main tasks: i) identification of the transferred reporter molecules, and ii) evaluation of their detection with probes targeting those reporter sites. The former was performed by visualizing, over the sample area, the distribution of spots corresponding to fluorophores directly conjugated to each reporter molecule (Figure 11).

[0414] The second part of the analysis consisted in detecting the reference reporter molecules with a set of oligonucleotide sequences or probes carrying many fluorophores, each reporter molecule carrying separately two distinct stretches of nucleotides that are the hybridization targets for detection system 1 and detection system 2. The experiment alternated between injection of the detection systems and "stripping" cycles aimed at removing the probes of one system before adding those of the other, allowing us to visualize which target region of the reporter molecule was detected in each cycle (Figure 12).

[0415] To further investigate the detection of the reporter molecules, we performed an analysis of individual images that constituted the entire sample area. Specifically, we focused on a set of four adjacent fields-of-view (FoV) that overlapped one of the tissue samples. Across these FoVs, we extracted spots detected by system 1 (Figure 13A; detection rate 0.166) and system 2 (Figure 13B; detection rate 0.284), as well as spots that were co-detected by both systems (Figure 13C; detection rate 0.098), and referred to the latter as spots of the reference reporter molecules. (Figure 13D; N=1173).

[0416] Results: As explained above, the first objective of the analysis was to confirm that fluorophore-bearing molecules could be transferred to a surface to be used for detection. Figure 11 clearly shows that the reporter molecules were correctly transferred to the surface and were in the expected location. The second objective was to demonstrate that these molecules could be detected using a cyclic detection system. Figure 12 shows that the regions with higher reporter molecule density are also the regions that generate higher signal intensity from the detection system in the detection cycles (cycles 2, 4, 6 and 8). In addition, Figure 13 shows that both detection system 1 and detection system 2 can hybridize to their target sites (Figures 13A-B), and the overlap between the two (Figure 13C) specifically localizes to where the majority of the reporter molecules can be found (Figure 13D). Taken together, this demonstrates that i) a sufficient number of molecules were transferred from the tissue to the surface, and ii) that this approach can detect the presence of these molecules with a high degree of confidence.

[0417] Example 6 Oligonucleotide Design In some embodiments of the method, the following oligonucleotides can be used:

[0418] Left targeting oligonucleotide (conjugate arm):

[0419] [Table 2]

[0420] Right targeting oligonucleotide (conjugate arm):

[0421] [Table 3]

[0422] Sprint:

[0423] [Table 4]

[0424] Left reporter oligonucleotide:

[0425] [Table 5]

[0426] Right reporter oligonucleotide:

[0427] [Table 6]

[0428] Modifications of this oligonucleotide are described below. / 5AzideN / : Azide modification attached via NHS ester / 5Phos / : phosphorylation U Deoxyuridine * Phosphorothioate bond / 3AzideN / Azide modification attached via NHS ester / 3Bio / Biotin

[0429] In this embodiment, the left target oligonucleotide and the right target oligonucleotide are bound to the antibody via their azide groups, and the antibody is bound to the sample. After binding, the sample is incubated with a ligase and a splint oligonucleotide. The adjacent target oligonucleotides become ligated to each other in a ligation mediated by the splint oligonucleotide. In the next step, the left and right reporter oligonucleotides are hybridized to the sample with the splint still hybridized to the ligation product. The left and right reporter oligonucleotides hybridize to sites in the ligation product adjacent to the splint, and the reporter oligonucleotide is ligated to the splint to generate the reporter molecule. After the reporter molecule is generated, the sample is treated with UDG or USER to cleave the ligation product with uracil or to remove uracil. This reduces the Tm of the interaction between the reporter molecule and the underlying ligation product, allowing the reporter molecule to be easily released. This embodiment is shown in FIG. 2B.

[0430] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those skilled in the art in light of the teachings of this invention that certain changes and modifications can be made without departing from the spirit or scope of the appended claims.

Claims

1. An in vitro method for analyzing a sample, comprising: (a) contacting an oligonucleotide or a conjugate comprising said oligonucleotide with a planar biological sample that is said tissue section under conditions such that said oligonucleotide or said conjugate specifically binds to a site in or on said tissue section; (b) performing in situ one or more steps for releasing and / or extending said oligonucleotide to generate a reporter probe; (c) moving all or a part of said reporter probe from said tissue section to a planar support that does not contain an array of oligonucleotides so as to preserve the spatial relationship of said reporter probe in said tissue section, said moving comprising placing said tissue section on said support and moving said reporter probe to the surface of said support by diffusion, wherein said planar support is a glass support; (d) detecting said reporter probe on said glass support by microscopy; comprising Step (d) comprises directly or indirectly hybridizing one or more labeled oligonucleotides to said reporter probe and then analyzing the binding pattern of said labeled oligonucleotides by microscopy, said method not including any nucleic acid amplification step, method.

2. Step (a) comprises hybridizing said oligonucleotide with said tissue section under conditions such that the oligonucleotide hybridizes to endogenous RNA or DNA in said tissue section, Step (b) comprises ligating together any oligonucleotides hybridized to adjacent sites in said RNA or said DNA via ligation or gap fill / ligation, the method according to claim 1.

3. The tissue section contains ligation products from a proximity ligation assay, Step (a) includes hybridizing the oligonucleotide with the tissue section under conditions where the oligonucleotide hybridizes to the ligation product, Step (b) includes ligating together any oligonucleotides that hybridize to adjacent sites in the ligation product via a ligation or gap fill / ligation reaction. The method according to claim 1. **Claim 4** The oligonucleotide is exonuclease-sensitive, but the reporter probe is exonuclease-resistant, Optionally, the method further includes treating the tissue section with exonuclease between step (b) and step (c). The method according to claim 1. **Claim 5** Step (a) includes contacting the tissue section with an antibody-oligonucleotide conjugate under conditions where the antibody binds to a site in or on the tissue section, Step (b) includes releasing the oligonucleotide or an extended product of the oligonucleotide from the conjugated antibody to generate the reporter probe. The method according to claim 1. **Claim 6** The reporter probe is generated via a ligation or gap fill reaction, or The reporter probe is generated via a primer extension reaction. The method according to claim 1. **Claim 7** The releasing is performed by contacting the tissue section with the support after step (a) and then heating the tissue section. The method according to claim 1. **Claim 8** The set of probes is hybridized and washed away in repeated cycles to decode individual reporter molecules. The method according to claim 1. **Claim 9** The method according to claim 1, wherein the tissue section contains mammalian cells.

10. An in vitro method for analyzing a planar biological sample, comprising: (a) performing an in situ proximity assay on one or more pairs of binder-oligonucleotide conjugates bound to the sample to generate a proximity assay reaction product; (b) moving the nucleic acid reaction product onto a planar support that does not contain oligonucleotides so as to preserve the spatial relationship of the proximity assay reaction product in the sample, wherein the moving comprises placing the tissue section on the support and moving the reporter probe to the surface of the support by diffusion, and the planar support is a glass support; (c) detecting the proximity assay reaction product on the support. Step (c) comprises: (i) labeling the proximity assay reaction product on the support; (ii) imaging the support to generate an image of the site where the proximity assay reaction product is bound to the glass support.

11. The method according to claim 10, wherein the proximity assay comprises any combination of ligation, primer extension, and gap fill / ligation reactions involving oligonucleotides of the binder-oligonucleotide conjugate.

12. The method according to claim 10, wherein step (c) comprises hybridizing one or more labeled oligonucleotides directly or indirectly to the nucleic acid reaction product.

13. The method according to claim 12, wherein in step (c), the proximity assay reaction product is detected by hybridization to a defined nucleic acid structure composed of a predetermined number of oligonucleotides and a predetermined number of labeled oligonucleotides.

14. The method according to claim 13, wherein the structure is nucleated by at least two hybridization events to the proximity assay reaction product.

15. The method according to claim 14, wherein the at least two hybridization events include a first hybridization to a first sequence in the proximity assay reaction product and a second hybridization to a second sequence in the proximity assay reaction product.

16. The method includes comparing the image generated in step (a) with an image of the sample, or The method according to claim 10, wherein the image of the sample is generated by staining the sample with a microscopic stain.

17. The method according to claim 10, further comprising removing the sample from the support between step (b) and step (c).

18. The method according to claim 10, wherein the biological sample is a tissue section.

19. The method according to claim 18, wherein the tissue section is a formalin-fixed paraffin-embedded (FFPE) tissue section.

20. The method according to claim 10, wherein the binder in step (a) is an oligonucleotide probe, an antibody, or an aptamer.

21. The diffusion is assisted by electrostatic force, electric force, or magnetic force, and the method according to any one of claims 1 to 20.

22. The planar support is a denatured glass and / or a functionalized glass, and the method according to any one of claims 1 to 20.

Images